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ABSTRACT: 
Introduction. It is fully recognized that cancer patients are at significant risk of developing 
thrombotic events (VTE). The prevention of such complications is of the utmost importance from a 
clinical point of view, seeing as they play a considerable part in the morbidity and mortality of these 
patients. The main issue is that the pathogenesis of the cancer-associated coagulopathy is complex 
and multifactorial. To assess the level of risk and identification of patients at high risk for thrombosis, 
the guidelines recommend including the detection of plasma thrombotic markers in “score systems” 
combining clinical and biological markers. However, current scores have been shown to perform 
poorly in predicting VTE in cancer patients. Thus, the identification of novel biomarkers associated 
with the grade of hypercoagulability in individual malignancies is required to drive the development 
of cancer type–specific scoring systems with improved predictive value.  
 
Aim of the study. We conducted a longitudinal cohort study to evaluate the trend of several 
coagulation parameters in patients with gastro-intestinal cancer with particular focus on circulating 
microvesicles (MVs) and MV-tissue factor (TF) activity. Our primary outcome was the description of 
coagulation fluctuations over a 6-month period following cancer diagnosis and the secondary outcome 
was the association between coagulation parameters and the occurrence of VTE complications. 
 
Material and Methods. Patients with a new diagnosis of gastro-intestinal cancer who underwent 
surgery were consecutively enrolled at the Padua University Hospital. Exclusion criteria were: cancer 
recurrence, severe liver or renal failure, Karnofsky Performance Status <60%, recent venous/arterial 
thromboembolism, pregnancy/puerperium, overt/recent sepsis. Longitudinal blood samples were 
collected at baseline, 7 days after surgery, 1 and 6 months after surgery. Each patient was followed for 
at least 6 months and for a maximum of 12 months. The primary outcome was the evaluation of 
coagulative parameters trend over a 6-month period following the diagnosis. Coagulation test 
performed included: factor (F)VIII and fibrinogen levels; D-Dimer and plasminogen activator 
inhibitor (PAI-1) antigen; hereditary thrombophilia; thromboelastometry; contact activation system 
(FXIIa-C1-inhibitor (C1INH), FXIa-C1INH and KAL-C1INH complexes); MV-TF activity; 
circulating MVs. Clinical outcomes recorded during the follow-up were: i) surgical radicality (i.e. 
complete or incomplete); ii) cancer severity (i.e. localized or advanced cancer); iii) any thrombotic 
event including superficial vein thrombosis, symptomatic or asymptomatic VTE or thrombosis in 
unusual sites. The secondary outcome was the association between the coagulative profile at the 
different time-points and the clinical outcomes.    
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Results. Ninety-three patients (25 with pancreatic, 33 with colon and 35 with gastroesophageal 
cancer) were enrolled. The median clinical follow-up was 6 months [6-8.5] for pancreatic, 8 months 
[7-11] for colon, and 6.5 months for gastric cancer [6-9.25]. VTE incidence rate was 9.21 [95%CI 
3.37-20.4] per 100 person-years for pancreatic cancer, 6.69 [95%CI 2.13-16.2] per 100 person-years 
for colon and 10.4 [95%CI 4.24-21.7] per 100 person-years for gastric cancer. The subgroup of 
pancreatic cancer at baseline showed increased levels of FVIII, D-Dimer, PAI-1 antigen, MV-TF 
activity and circulating MVs compared with the other cancer subtypes.  
In the overall cancer population, baseline contact system complexes were increased compared to 
levels measured in a reference healthy population, and pancreatic and gastric cancers showed the 
highest activation. Patients receiving chemotherapy at the 6-month time point showed significantly 
higher levels of FXIIa-C1INH and kallikrein-C1INH complexes compared to patients without 
chemotherapy.  
In a multivariate model, levels of MV-TF activity were independent predictors of incomplete surgical 
resection (OR 2.25 [1.25-7.0]) and cancer severity (OR 1.87 [1.20-3.8]).  
We observed that the majority of MVs detected were small (diameter 0.2-0.4 µm). Moreover, we 
confirmed that PS-negative MVs are the majority and thus PS is not the most suitable marker to detect 
the total number of MVs. MV-TF activity correlated with PS+MVs big and small, with endothelial 
MVs and big tumour MVs. Endothelial MVs, as well as MV-TF activity, showed a positive 
association with surgical radicality and cancer severity (OR 1.19 [1.04-1.36] and 1.30 [1.05-1.6], 
respectively).  
Levels of MV-TF activity ≥0.19 pg/mL conveyed a 2.38 [1.81-4.11] HR for VTE occurrence. 
Furthermore, baseline levels of FXIa >0.61 nM conveyed a 1.66 [1.02-2.9] HR to develop VTE over a 
median follow-up period of 6 months after diagnosis. This prediction model was adjusted for age, sex, 
BMI, cancer type, severity, and surgical radicality.  
 
Conclusions. Hypercoagulability in gastro-intestinal cancer is mainly mediated by high levels of 
FVIII, increased levels of complexes derived from the activation of the contact system, high MV-TF 
activity and increased levels of PS+MVs, endothelial and tumour MVs. Pancreatic cancer showed the 
most hypercoagulable profile. The prothrombotic factors remained altered up to 6 months after 
surgical resection of the neoplasm even in patients with surgical radicality, indicating that cancer-
associated hypercoagulability persists months after tumour removal. Increased MV-TF activity and 
endothelial MVs are independent predictors of advanced disease and incomplete surgical resection. 
Finally, baseline increased levels of MV-TF activity and FXIa were independent predictors of VTE 
occurrence over the 6 months following cancer diagnosis. As TF is upregulated in cancer, it seems 
reasonable to hypothesize that concomitant activation of both the intrinsic and extrinsic pathways may 
act synergistically to produce a highly prothrombotic state in cancer.  
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1. Introduction 
 
Patients with cancer are at increased risk to develop venous thromboembolism (VTE), an association 
that is commonly known as Trousseau’s syndrome (1, 2). The clinical manifestations of cancer-
associated VTE include deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as 
visceral or splanchnic vein thrombosis (3). Indeed, cancer is a strong and independent risk factor for 
VTE (4, 5). It has been estimated that ~20% of all first VTE events are associated with cancer (6). 
Additionally, cancer-associated thrombosis is also linked to a worse prognosis, and VTE is the second 
leading cause of death in cancer (6). Cancer induces a systemic hypercoagulable state that elevates the 
baseline thrombotic threshold of affected patients. This hypercoagulable state is the result of a 
complex interplay among cancer cells, host cells and the coagulation system as part of the host 
response to cancer. Moreover, several compounding risk factors for VTE usually coexist in cancer 
patients which may be classified as patient-, tumour- or treatment-related, may additively exceed the 
threshold for clinically overt thrombosis (Figure 1).  
 
 
Figure 1: Longitudinal risk of thrombosis in a patient with cancer. Normal individuals maintain a 
hemostatic equilibrium whereas cancer patients are typically in a pre-thrombotic state, and at risk of 
developing overt thrombosis. 
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1.1 Epidemiology of cancer-associated thrombosis 
In 1865, Armand Trousseau, a French physician, was one of the first to describe an association 
between thrombosis and cancer (1). Although the association had already been reported earlier in 
1823 by Jean Baptiste Bouillaud (7), the condition was later called Trousseau syndrome, perhaps 
because of the irony of Trousseau diagnosing the disease on himself and dying from it in 1867. Since 
then, many studies have confirmed the association between cancer and venous thrombosis and 
demonstrated that the incidence of VTE in cancer patients is high and it has risen steadily over the 
past few decades (6).  
Overall, cancer accounts for an estimated 18 % (95 % confidence interval [CI]: 13.4–22.6 %) of the 
total number of VTE cases (5). According to the results of a well-known, recent registry, the Registro 
Informatizado de Enfermedad TromboEmbólica (RIETE), which included >35,000 consecutive 
symptomatic venous thrombosis patients from 2001 to 2011, active cancer was reported in 6075 
patients (17%) (8). Moreover, the frequency of VTE in cancer patients admitted to hospital ranges 
from 2 % to 12 % (9, 10). Based  on  hospitalization  rates  for  VTE,  the  incidence  rate  for  cancer-
associated VTE was estimated 8 patients per 1,000 patients/year (11). According to a recent UK 
cohort study that included 6,592 cancer-associated VTEs, the incidence rate of first VTE in patients 
with active cancer was 5.8 (95 % CI, 5.7-6.0) per 100 person-years and the overall incidence rate for 
recurrence was 9.6 (95 % CI, 8.8-10.4) per 100 person-years (12). On the other hand, cancer patients 
have a several-fold increased risk of venous thrombosis compared with the general population or 
patients without cancer, with relative risks (RRs) ranging from 4 to 7 (4, 11, 13). Particularly, the risk 
of VTE was increased sevenfold in patients with cancer compared with patients without (Odds Ratio 
[OR] 6.7; 95% CI: 5.2-8.6). By linkage of 4 United Kingdom databases, Walker and coworkers 
estimated the RR of VTE in cancer versus age-matched non-cancer controls from the general 
population to be 4.7 (hazard ratio [HR] 4.7; 95% CI: 4.5-4.9 (4). Similar results were reported from a 
Danish population-based cohort of 57,591 incident cancer cases that were followed over time for 
venous thrombosis occurrence, together with 287,476 individuals without cancer from the general 
population. Non-cancer controls were matched for age, gender, and county of residence. After 
adjustment for comorbid conditions, the risk of VTE was also 4.7 times higher in cancer patients 
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compared with the non-cancer subjects (RR 4.7; 95% CI: 4.3-5.1) (11). More recently it was found 
that the incidence rate of VTE was 54-times higher than that reported in the non-cancer cohort (5,800 
vs 107/100,000 person-years) considering the active-cancer cohort (the denominator consisted of 
active-cancer time periods in contrast to any time after the first cancer diagnosis) (12). Although these 
RRs demonstrate a strong association between cancer and venous thrombosis, absolute risks are 
clinically more meaningful when trying to convey a patient’s actual risk of venous thrombosis. The 
reported absolute risk (cumulative incidence) of VTE in cancer patients varies widely (1%-8%) 
depending on patient population, duration of follow-up, calendar period, and the method of detecting 
and reporting venous thrombotic events (6). In the Vienna Cancer and Thrombosis Study (CATS)–a 
large, prospective observational study–the  cumulative  incidence  of  VTE  among  cancer  patients  
over  the  median observation period of approximately 19 months was 7.4% (14).  
In a large registry study, cancer was found to be the strongest  independent risk factor for all-cause 
and PE-related mortality in patients with VTE (8). In the same study, 3% of deaths in cancer patients 
were PE-related versus 1% of deaths in non-cancer patients (p <0.001) (8). Additionally, survival 
rates tend to be significantly lower and prognosis significantly worse in cancer patients with VTE 
relative to those without (15-17). For instance, in a Danish registry study, patients with cancer 
diagnosed concurrently with VTE had a significantly lower one-year survival rate (12 % vs 36 %; p 
<0.001) and significantly more distant metastases (prevalence ratio [95 % CI]:  1.26 [1.13 to 1.40]) 
compared with cancer patients without VTE (17).  
In addition to the increased risk of VTE in cancer patients and the worse prognosis linked to cancer-
associated VTE, healthcare costs are approximately 40 % to 50 % higher in cancer patients with  VTE 
as compared with cancer patients without VTE (18, 19). These increased healthcare costs are 
primarily driven by higher inpatient and outpatient costs (19, 20). In a population-based, longitudinal 
cohort study, after adjusting for cofactors including age, sex, and cancer type and stage, the direct 
five-year healthcare costs were significantly higher in cancer patients  with  VTE  versus  cancer  
patients  without  VTE  (approximately  $49,000  vs  $27,000  in  2013  US  dollars;  p ≤0.001) (20). 
Figure 2 and Table 1 and 2 summarize the epidemiology and burden of VTE in cancer.  
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Figure 2. Pooled rates of venous thromboembolism per 1,000 person-years (p-ys) for studies 
where follow-up started at the time of cancer diagnosis. Numbers in brackets refer to the number 
of studies that contributed to the pooled estimate (from Horsted F. et al. 2012 (21)). 
 
 
Table 1: Risk of venous thromboembolism (VTE) in cancer overall with pooled incidence rates 
and 95% confidence intervals (CI) obtained from random effects meta-analysis (21). 
 
First author (year)[ref] 
Total 
participants 
Total person-years 
of follow-up Total VTE 
Incidence rate/1000 
person-years  
(95%CI) 
Average 
follow-up 
(months) 
Average risk      
Blom (2006)(22) 66,329 31,867 815 25.6  (23.9-27.4) 6 
Chew (2006)(23) 235,149 389,150 3,775 9.7  (9.4-10.0) 20 
Cronin-Fenton (2010)(24) 57,591 127,492 1,023 8.0  (7.6-9.5) 27 
Pooled incidence rate    12.6  (7.0-22.6)  
Heterogeneity (I ² =99.7%)      
High risk      
Sallah (2002)(9) 1,041 2,256 81 35.9 (28.9-44.7) 26 
Otten (2004)(25) 206 133.1 15 112.7 (67.9-186.9) 8 
Ay (2009)(26) 821 1,126 62 55.1  (42.9-70.6) 16 
Hall (2009)(27) 14,214 9,249 489 52.9   (48.4-57.8) 8 
Connolly (2010)(28)  4,405 904,5 93 102.8   (83.9-126.0) 2 
Abdel-Razaq (2010)(29) 606 111.0 21 189.2  (123.4-290.2) 2 
Di Nisio (2010)(30) 1,921 1,281 39 30.5  (22.3-41.7) 8 
Reeves (2010)(31) 176 17.2 2 116.3  (29.1-464.9) 1 
Pooled incidence rate 
 
 
  68.0 (48.0, 96.4)  
Heterogeneity (I ² =93.4%)      
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Table 2: Incidence rate (95 % CI) of first VTE per 100 person-years by cancer type and age 
among patients with active cancer (from Cohen et al. 2017 (12)). 
 
 
 
1.2 Risk factors for venous thrombosis in cancer patients 
Cancer is a heterogeneous disease, and its different types and stages should be taken into account 
when determining the risk of VTE. Also several patient- and treatment-associated factors are known 
to increase the risk of thrombosis. Particularly, when considering cancer patients, risk factors for 
developing VTE can be grouped into tumour-related factors, patient-related factors and treatment-
related factors (3, 6, 32) (Table 3). 
 
 
 
 
Age Pancreas Stomach Brain Ovary Lung 
 
 
Haematologic 
 
 
Colon 
 
 
Breast 
<18 
- - - - - 0.7 
(0.3–1.6) 
- - 
18-29 
- - - - - 1.5 
(0.6–3.1) 
- - 
30-39 
25.8 
(7.0–66.1) 
- 
5.7 
(2.5–11.3) 
5.7 
(2.5–11.3) 
14.5 
(5.8–29.8) 
3.0 
(1.7–4.9) 
7.2 
(2.9–14.8) 
2.4  
(1.4-3.8) 
40-49 
17.1 
(8.5–30.5) 
12.6 
(6.1–23.2) 
10.5 
(6.7–15.7) 
10.5 
(6.7–15.7) 
9.2 
(5.9–13.7) 
2.9 
(2.0–4.1) 
6.1 
(4.1–8.8) 
2.0  
(1.5–2.6) 
50-59 
21.4 
(16.0–28.2) 
13.2 
(8.7–19.1) 
14.5 
(10.3–19.8) 
14.5 
(10.3–19.8) 
11.4 
(9.5–13.6) 
4.7 
(3.8–5.7) 
5.4 
(4.3–6.7) 
2.4  
(1.9–2.9) 
60-69 
17.1 
(13.6–21.4) 
11.0 
(8.2–14.5) 
16.3 
(12.2–21.4) 
16.3 
(12.2–21.4) 
11.0 
(9.8–12.4) 
4.7 
(4.0–5.4) 
6.7 
(5.8–7.7) 
3.3  
(2.8–4.0) 
70-79 
12.3 
(9.6–15.5) 
13.1 
(10.7–15.9) 
15.3 
(10.6–21.3) 
15.3 
(10.6–21.3) 
10.0 
(8.9–11.2) 
4.6 
(3.9–5.3) 
7.4 
(6.6–8.3) 
4.3  
(3.5–5.2) 
80-89 
11.8 
(8.5–16.0) 
7.4 
(5.3–10.0) 
7.0 
(2.6–15.3) 
7.0 
(2.6–15.3) 
8.4 
(7.1–9.9) 
5.4 
(4.5–6.3) 
6.5 
(5.6–7.6) 
4.7  
(3.7–5.9) 
>89 
- 4.2 
(1.2–10.9) 
- - 6.3 
(3.3–11.0) 
2.8 
(1.4–5.2) 
7.6 
(5.0–11.1) 
6.1 
(3.9–9.0) 
Total >18 
14.6 
(12.9–16.5) 
10.8 
(9.5–12.3) 
12.1 
(10.3–14.0) 
12.1 
(10.3–14.0) 
10.1 
(9.5–10.8) 
4.5 
(4.1–4.8) 
6.7 
(6.3–7.2) 
3.2 
(2.9–3.4) 
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Table 3: Overall risk factors for cancer-associated thrombosis.  
Cancer-related Treatment-related Patient-related 
- Anatomical site of cancer  
- Advanced stage of cancer  
- Initial period after cancer diagnosis  
 
- Major surgery 
- Hospitalization 
- Chemotherapy and hormonal 
therapy 
- Anti-angiogenic therapy 
- Erythropoiesis stimulating 
agents 
- Central venous catheters 
- Blood transfusions 
- Older age 
- Female gender 
- Race (black ethnicity) 
- Common comorbidities 
(diabetes, obesity, previous VTE, 
atherosclerosis, inflammation…) 
- Hereditary trombophilia 
 
1.2.1 Cancer-related risk factors 
Tumour-related factors include: 
- primary site 
- grade 
- cancer stage  
- time since diagnosis 
Extensive work has been published on type of malignancy and subsequent risk of venous thrombosis. 
A 2006 large registry study assessing 20 of the most common cancers reported the highest incidence 
of concurrently diagnosed VTE in patients with metastatic cancers of the pancreas, stomach, lung, 
uterus, bladder, and kidney (15). In  general,  the  types  of  cancer  most  often  associated  with VTE 
are gastric and pancreatic cancers (3, 4, 6, 11, 15, 32-34). Other cancers associated with a high risk of 
VTE include brain, gynaecological cancers, lung, renal, bladder, bone, and haematological 
malignancies (4, 6, 11, 13, 15, 32-34). Relatively low risks are generally seen in patients with breast 
or prostate cancer.  
Although VTE incidence per type of cancer varies in different studies, a clear positive association 
can be observed with 1-year relative mortality of the cancer type, as a measure of the biological 
aggressiveness of the cancer, and the associated thrombogenic potential. Patients with metastatic 
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cancers have a significantly greater risk of developing VTE relative to patients with localised cancer 
(13, 15, 16, 32). In the above mentioned CATS, the cumulative probabilities of VTE  after six months 
in cancer patients with local, regional, or distant  stage cancer were 2.1 %, 6.5 %, and 6.0% (p = 
0.002) (35). Interestingly enough, the cumulative probability was similar in patients with regional or 
distant stage cancers while patients with local stage cancer had a much lower VTE risk (35). Finally, 
the histological grading is also an important risk marker. Once again, in CATS the rate of VTE was 
roughly twice as high in patients with high-grade tumours compared with those with low-grade 
tumours (HR  [95 %  CI],  2.0  [1.1–3.5];  p  = 0.015), after adjusting for cofactors including distant 
metastases, sex, and age (36). There is also an observed time-dependent association between VTE and 
cancer, with most VTE events occurring in the first few months after cancer diagnosis and decreasing 
thereafter (4, 6, 13, 15, 16, 33). In the MEGA study, the risk of venous thrombosis was highest in the 
first 3 months after cancer diagnosis (OR 53.5; 95% CI: 8.6-334.3), was decreased but still high in the 
period between 3 and 12 months (OR 14.3; 95% CI: 5.8-35.2), and decreased to almost no elevated 
risk 10 years after cancer diagnosis (13). This phenomenon has been shown for all types of cancer in 
the large follow-up study by linkage of 4 United Kingdom databases (4). This change in risk over 
time highlights why follow-up studies regarding VTE incidence in cancer patients need to start at time 
of cancer diagnosis. If follow-up is started at a later point, the incidence will be lower, and studies 
cannot be compared directly. From a pathophysiological point of view, there are several possible 
explanations for the increased risk of VTE in the first few months after diagnosis compared with the 
period thereafter. First, several cancer treatment modalities increase the risk of VTE, inducing a high 
risk directly after diagnosis and start of treatment. Second, a proportion of treated cancer patients will 
go into remission, leading to a reduced thrombotic risk thereafter. A third explanation is that a 
proportion of cancer patients will succumb to the disease over time. The occurrence of such a 
competing event (death) will prevent thrombotic events from being observed (6).  
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1.2.2 Treatment-related risk factors 
Treatment-related  factors  include  both  mechanical causes (surgery and central venous catheters) 
and pharmacologic  agents,  such  as  chemotherapeutic  and hormonal  agents, antiangiogenic and 
erythropoiesis-stimulating agents (3, 5, 6, 11, 13, 32, 33). In particular, platinum-based 
chemotherapies (e.g. cisplatin) and anti-angiogenesis treatments (e.g. bevacizumab) are frequently 
associated with VTE (33, 37-39). Results from a clinical trial in advanced gastroesophageal cancer 
patients showed varying rates of VTE for either 1 of 4 epirubicin/platinum/fluoropyrimidine 
combination regimens during treatment until 30 days after the last treatment cycle. A higher 
cumulative incidence of VTE was observed in patients receiving a cisplatin-containing combination 
regimen (12.2%) compared with oxaliplatin (6.5%) (40). According to the results of 2 meta-analyses 
of clinical trials, patients treated with  cisplatin  or  bevacizumab  therapy  were  at  significantly  
higher risk for VTE relative to patients treated with non-cisplatin or non- bevacizumab therapies (RR 
[95 % CI]: 1.67  [1.25–2.23]  and  1.33  [1.13–1.56],  respectively)  (41, 42). Other treatments 
associated with VTE in cancer patients include thalidomide, hormonal therapy, erythropoiesis-
stimulating agents, and red blood cell or platelet transfusions (6, 13, 32-34). In a randomized trial in 
postmenopausal women with node-positive primary operable breast cancer (with positive estrogenic 
and progesterone receptor status), the cumulative incidence of VTE was assessed for women 
randomized to 2 years of tamoxifen or to tamoxifen (2 years) plus chemotherapy for 6 months. The 
cumulative incidence in the tamoxifen only group was 2.6% vs 13.6% in the combined treatment 
group (43). Moreover, two systematic reviews of randomized controlled trials demonstrated that 
cancer patients treated with erythropoiesis-stimulating agents in addition to red blood cell transfusions 
had an increased risk of VTE over patients not additionally treated with these compounds (with a RR 
of 1.7) (44, 45). Additionally, surgery is a well-known risk factor for VTE, both in cancer and non-
cancer population. In cancer patients, risk of 90-day postoperative VTE is reported to be twice as high 
as in non-cancer patients (46).  
 
1.2.3 Catheter-related thrombosis 
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Central venous catheters (CVCs) have been shown to facilitate chemotherapy, transfusions, 
antibiotics, and parenteral nutrition delivery. Furthermore, they allow readily available venous access 
for laboratory testing and have been shown to improve patients' quality of life and reduce health care 
costs by allowing patients to receive parenteral therapy at home (47). All CVCs are designed to have 
their catheter tip dwelling at the junction of the superior vena cava and the right atrium within the 
central venous system (48). CVCs can be classified as tunneled or non-tunneled catheters, 
peripherally inserted central catheter (PICC), implanted ports and dialysis catheters (48). Different 
types of CVCs have distinctive features including varying numbers of lumens (single, double or 
triple) or the addition of valves which prevent reflux of blood back into the lumen of the catheter. 
Clinicians need to use the smallest-diameter catheter that will fulfil the patient's need (e.g. multiple 
lumens might be required for chemotherapy infusion in cancer patients) and ensure that the CVC is 
removed when it is no longer used to minimize the risk of any associated complications (47). Risk 
factors for catheter-related thrombosis can be divided into those that are intrinsic to the CVC (or its 
insertion) and those extrinsic or related to patient's characteristics (Table 4). The largest systematic 
review and meta-analysis on this topic have shown that the type of CVC (PICC > implanted ports), its 
location (e.g. junction of the superior vena cava and the right atrium) and the insertion site (femoral > 
subclavian > jugular) are important intrinsic predictors of thrombosis (49). Other possible risk factors 
include CVC diameter and left-sided insertions (50). Cancer, particularly extensive or metastatic 
disease, has consistently been shown to be one of the strongest risk factors for catheter-related 
thrombosis (51, 52).  A systematic review of 64 studies evaluating the risk of upper extremity DVT in 
29,503 adults who had a CVC, showed that the mean rates of superior arm vein thrombosis were 4.9% 
overall, 6.7% in patients with cancer, and 13.9% in patients admitted to critical care (51). Finally, a 
systematic review of 10 studies of 1000 cancer patients with a CVC found that those with Factor V 
Leiden or prothrombin gene mutation had a >4-fold greater odds of catheter-related thrombosis (53).  
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Table 4: Risk factors associated with catheter-related thrombosis (From Rajasekha and Streiff 
2017 (54)).  
Device-related Patient-related Treatment-related 
- Multiple insertion attempts 
- Catheter insertion site 
(femoral.>jugular>subclavian) 
- Large catheter size to vein diameter ratio  
- Catheter subtype (peripherally-inserted 
[PICC]>centrally-inserted>implanted port) 
- Catheter infection 
- Improper catheter position (not at atriocaval 
junction) 
- No. of lumens and catheter size (6F triple-
lumen>5F double-lumen>4F single-lumen) 
-Material (polyethylene/polyvinylchloride 
>silicone/polyurethane) 
- Previous catheter 
- Malignancy 
(metastatic>localized) 
- Recent trauma/surgery 
- Previous VTE 
- End-stage renal disease 
- Critically ill patients 
- Older age 
- Systemic or catheter-
related infection 
- Immobilization 
- Inherited thrombophilia 
 
- Ongoing cancer therapy 
- Radiation therapy  
- Bolus (vs diluted) 
chemotherapy infusions 
- Antiangiogenic agents 
and platinum therapy 
- Erythrocyte stimulating 
agents 
- Parenteral nutrition 
- Surgery 
 
 
1.2.4 Patient-related risk factors 
Several traditional risk factors for thrombosis are additionally present in many cancer patients such as 
older age (≥65), prolonged immobility, obesity, prior history of VTE, and comorbidities (4, 15, 33, 
34). In the California Cancer Registry study in colorectal cancer patients, a significant predictor of 
VTE during the first year after cancer diagnosis was the presence of >3 comorbid conditions (HR 2.0; 
95% CI: 1.7-2.3) (55). Not all studies have replicated the association between advanced age or obesity 
and the increased risk for VTE in cancer patients, whereas the occurrence of varicose veins and prior 
VTE has also been associated with VTE in cancer patients (32, 37, 56, 57). Finally, prothrombotic 
mutations are additionally reported to influence the risk of thrombosis in cancer patients. For 
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example, there appears to be a correlation between the factor V Leiden mutation and VTE risk (13, 
53). Cancer patients with factor V Leiden were reported to have a twofold increased risk of VTE 
compared with cancer-free non carriers (adjusted OR 2.2; 95% CI: 0.3-17.8) (13, 58). Similarly, in a 
prospective study conducted on women with breast cancer undergoing adjuvant tamoxifen treatment, 
patients who developed VTE were significantly more likely to have a factor V Leiden mutation 
compared with patients without VTE (59).  
 
1.3 Clinical presentation of cancer-associated thrombosis 
Bilateral DVT seems to be more common among cancer patients than in non-cancer patients (6). A 
study showed that rates of symptomatic bilateral lower limb DVT, symptomatic ilio-caval thrombosis, 
and upper limb DVT were higher in cancer patients compared with cancer-free patients (8.5% vs 
4.6%, 22.6% vs 14.0%, and 9.9% vs 4.8%, respectively) (60). However, rates of PE and symptomatic 
proximal DVT were similar. The relatively high incidence of upper limb DVT in cancer patients can 
explained, at least in part, by the frequent use of a CVC, as previously mentioned (51, 52). 
Furthermore, cancer has been commonly reported in rare forms of thrombosis such as Budd-Chiari 
syndrome, extrahepatic portal vein obstruction, and mesenteric vein thrombosis (61).  
 
1.3.1 Recurrent venous thrombosis and cancer 
Cancer patients are associated with a roughly two- to threefold increased risk of recurrent VTE 
compared with non-cancer patients (6, 62) (Table 5). Prandoni et al. followed 355 consecutive 
patients with a first DVT for 8 years and found a twofold risk of recurrent DVT in cancer compared 
with non-cancer patients (HR 1.7; 95% CI: 1.3-2.3) (62). Moreover, in a prospective cohort study 
including 842 DVT patients the 12-month cumulative incidence of recurrent VTE was found to be 
20.7% in cancer patients on conventional anticoagulant treatment vs 6.8% in non-cancer patients on 
anticoagulant treatment (63). Recurrence appeared to be related to extent of disease, classified 
according to the tumour node metastasis (TNM) classification. The highest recurrence rates in patients 
with extensive vs moderately or less extensive cancer, which again reflects the apparent correlation 
between aggressiveness of cancer and thrombogenic potential (6). A study conducted within the 
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above-mentioned RIETE enrolled patients with symptomatic acute VTE and studied the 3-month 
outcomes: 3805 out of the 18,883 participants had been diagnosed with active cancer. The study 
found a RR for recurrent PE of 2.0 and for recurrent DVT of 2.4 in patients with a cancer diagnosis 
>3 months before their first thrombotic event (64). At the moment, not much is known about the risk 
of recurrent VTE for different types of cancer and previous studies have yielded contradictory results 
(63, 64).  
 
Table 5: Incidence rate (IR, 95 % CI) of recurrent VTE per 100 person years by VTE type of 
first VTE among patients with active cancer (from Cohen et al. 2017 (12)). 
 
 
 
1.4 Role of biomarkers in cancer  
As stated by Strimbu and Tavel: “The term biomarker refers to a broad subcategory of medical signs 
observed outside the patient that can be measured accurately and reproducibly” (65). It is 
hypothesized that biomarkers of a prothrombotic state can be used to identify patients at increased 
risk for primary and recurrent VTE (39, 66, 67). Haematologic biomarkers associated with an 
increased risk of VTE in cancer patients include elevated platelet and/or leukocyte counts and low 
Time at risk of 
recurrent VTE 
Recurrent VTE IR 
(95%CI) 
Recurrence after first PE 
IR (95%CI) 
Recurrence after first DVT 
IR (95%CI) 
<180 days 
 
22.1 (19.9-24.4) 
 
24.0 (20.8-27.6) 
 
20.2 (17.3-23.4) 
180-365 days 
 
7.9 (6.2-9.8) 
 
7.3 (5.1-10.0) 
 
8.4 (6.1-11.4) 
1-<2 years 
 
6.6 (5.3-8.2) 7.1 (5.1-9.5) 
 
6.2 (4.4-8.4) 
2-<3 years 
 
4.1 (2.8-5.8) 
 
4.2 (2.4-7.0) 
 
3.9 (2.2-6.4) 
3-<4 years 
 
3.2 (1.8-5.1) 
 
3.1 (1.3-6.5) 
 
3.2 (1.4-6.0) 
4-<5 years 
 
2.5 (1.2-4.8) 
 
2.0 (0.4-5.9) 
 
2.9 (1.1-6.3) 
Total 
 
9.6 (8.8-10.4) 
 
10.5 (9.3-11.7) 
 
8.8 (7.8-9.8) 
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haemoglobin levels (Table 6). An elevated platelet count is strongly and independently associated 
with VTE in cancer patients (56, 66), with one study reporting a 3.5-fold increased risk of VTE in 
patients with platelet count ≥ 443×109/L (68).  
Other biomarkers independently associated with the presence of VTE in cancer patients in CATS 
include elevated plasma levels of soluble P-selectin (sP-selectin), prothrombin fragment 1+2 (F1+2), 
and D-dimer, as well as increased thrombin generation potential (32, 68-71). P-selectin, a cell 
adhesion molecule primarily found in endothelial cells and platelets, is believed to mediate the 
adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer cell 
growth/metastasis (72). F1+2 is considered a specific in vivo marker of thrombin generation; D-dimer 
is the primary degradation product of cross-linked fibrin and reflects the global activation of the 
haemostatic and fibrinolytic system (73, 74). In patients with colorectal cancer, the presence of 
preoperative positive D-dimer was associated with an increased risk of VTE during the first year post-
surgery in comparison with patients negative for D-dimer pre-surgery (HR [95 % CI]: 6.53 [1.58–
27.0]; p = 0.009) (75). Another biomarker linked to an increased risk of cancer-associated VTE is C-
reactive protein (CRP) (37), a marker of systemic inflammation (76). However, not all studies have 
been able to replicate the association between CRP and cancer-associated VTE (77). There are very 
few studies aimed the assessment of the longitudinal fluctuations in cancer-associated VTE 
biomarkers. A recent longitudinal study conducted over six months in patients with colorectal, lung, 
pancreatic, or brain cancer reported that cancer patients who developed VTE consistently showed 
significantly elevated haemostasis biomarker levels, including sP-selectin and D-dimer, throughout 
the entire 250-day observation period versus those patients who did not develop VTE (78). As there 
was no continuous increase in D-dimer levels prior to VTE occurrence (62), the added value of 
continuous biomarker monitoring, rather than a single measurement, in improving VTE prediction 
and patient care is not clear.  
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Table 6. Possible biomarkers of cancer-associated thrombosis 
 
Haematologic biomarkers 
P-Selectin 
Microvesicles-tissue factor activity 
D-dimer 
Prothrombin fragment 1 + 2 
Thrombin generation potential 
C- reactive protein 
Leukocytosis, Thrombocytosis, Anaemia 
Increased circulating soluble P-Selectin 
Increased in pancreatic cancer 
 
 
1.5 Risk assessment models of cancer-associated thrombosis 
Based on the aforementioned risk factors, models were developed to stratify VTE risk in cancer 
patients. The availability of predictive models can facilitate the management of cancer-associated 
thrombosis by allowing the identification of patients most at risk for thrombosis who may benefit 
from early thromboprophylaxis (6, 79). The first was developed by Khorana specifically for cancer 
patients undergoing chemotherapy (66). This model is based on five predictive variables: cancer site, 
platelet count, haemoglobin levels or the use of erythropoiesis-stimulating agents, leukocyte count, 
and body mass index. This model uses a simple scoring system, is based on readily accessible 
baseline clinical and laboratory data, and has been shown to accurately predict the short-term risk of 
symptomatic VTE in patients undergoing chemotherapy-based treatments. The Khorana score has 
been validated in both prospective and retrospective observational studies (39, 80-82) (Table 7). In the 
CATS the score was expanded by adding two laboratory biomarkers (i.e., P-selectin and D-dimer), 
and the prediction of VTE was considerably improved (80) (Table 7). More recently, another 
modified Khorana risk assessment score (i.e., the Protecht score) was designed by adding platinum- or 
gemcitabine-based chemotherapy to the five predictive variables for identifying high-risk cancer 
patients in a post-hoc analysis of the Protecht clinical trial (82). In the setting of multiple myeloma, 
Palumbo et al. published a risk assessment model for the prevention of thalidomide and lenalidomide-
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associated thrombosis (83). Finally, the Ottawa Score was developed to identify among patients with 
cancer and thrombosis those at highest risk of recurrent VTE, who may benefit from prolonged 
anticoagulant treatment (84, 85). The recent guidelines for prevention and treatment of VTE in cancer 
patients released by the American Society of Clinical Oncology (ASCO) remark that the thrombotic 
risk prediction cannot rely on the results of a single test. Instead, to assess the level of risk and 
identification of patients at high risk for thrombosis, the guidelines recommend including the 
detection of plasma thrombotic markers in “score systems” combining clinical and biological markers 
(79, 86) (Table 8). 
 
Table 7. Predictive model for chemotherapy-associated venous thromboembolism.  
Khorana VTE risk assessment score Points 
Site of cancer   - very high risk (stomach, pancreas) 
                          - high risk (lung, lymphoma, gynaecologic, genitourinary) 
2 
1 
Platelet count   ≥ 350 x 109/L 1 
Haemoglobin   < 100 g/L or use of red blood cell growth factors 1 
Leukocyte count > 11 × 109/L 1 
BMI ≥ 35 kg/m2 1 
Vienna VTE risk assessment score  
sP-selectin ≥ 53.1 ng/mL 1 
D-dimer ≥ 1.44 µg/mL 1 
0 score, low risk 
1-2 score, intermediate risk 
≥ 3, high risk. 
 
Table 8. Modified Khorana Score recommended by American Society of clinical Oncology 
(ASCO) (86).  
Characteristics Points 
Site of cancer   - very high risk (stomach, pancreas, brain) 
- high risk (lung, lymphoma, gynaecologic, bladder, testicular, renal) 
2 
1 
Platelet count   ≥ 350 x 109/L 1 
Haemoglobin   < 100 g/L or use of red blood cell growth factors 1 
Leukocyte count > 11 × 109/L 1 
18 
 
BMI ≥ 35 kg/m2 1 
0 score, low risk 
1-2 score, intermediate risk 
≥ 3, high risk. 
 
 
1.6 Mechanisms of thrombosis in cancer 
The pathogenesis of cancer-associated VTE is multifactorial and likely involves multiple overlapping 
pathways. All aspects of Virchow’s triad of venous stasis, hypercoagulability, and vessel wall injury 
(32, 87, 88) may all play a role in cancer-associated VTE, with the increased immobility, 
chemotherapy- and surgery-induced endothelial damage, and a cancer-induced state of 
hypercoagulability. Suggested mechanisms for cancer-associated hypercoagulability include direct 
coagulation pathway activation, inhibition of fibrinolytic activity, and induction of inflammatory 
responses (32, 79, 89-91) (Figure 3).  
 
 
Figure 3: Main mechanisms involved in cancer-related hypercoagulability.  
 
TF: tissue factor.  
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1.6.1 Direct coagulation activation 
 
Tumour cells themselves have been shown to contribute to the hypercoagulable state via the 
production of procoagulant factors (Figure 4). First, a positive correlation was observed between  
serum concentration levels of cancer procoagulant (CP), a cysteine proteinase believed to be produced 
by tumour cells and to direct activate coagulation factor (F)X (independently from FVII) (92) and  
fibrinogen  in  patients  with gastrointestinal adenocarcinomas (93).  
Among procoagulant proteins, the main mechanism by which cancer induces fibrin formation is 
suggested to be through an upregulation of tissue factor (TF) and through the production of TF-
positive microvesicles (MVs). Tissue factor (TF) is a transmembrane receptor that binds plasma factor 
VII/VIIa and triggers blood coagulation following vascular injury and in various diseases (94-96). 
Cancer cells are well known to express TF and release TF-positive MVs (96-99). TF expression 
increases with histologic grade in different cancer types, including pancreatic cancer (98, 100, 101). 
Patients  with  cancer  have been showed to  have  elevated  plasma  TF  concentration compared to 
individuals without cancer (102). In addition, in  one study TF expression in tumour cells was 
significantly correlated  with  the  development  of  VTE  in  women  with  ovarian  cancer (103). 
Two studies have reported a correlation between the level of TF in pancreatic and brain tumours and 
VTE (98, 101). In addition to this role in cancer-associated thrombosis, there have been reports 
relating to TF involvement in tumour growth and metastasis (104, 105). In fact, elevated TF 
expression has been reported to be associated also to the tumour endothelium. Activated oncogenes 
(K-ras, EGFR, PML-RARA, and MET) or inactivated tumour suppressors (eg, p53 or PTEN) lead to 
an increase in TF levels and activity, which presumably promotes not only hypercoagulability but also 
tumour aggressiveness and angiogenesis (2). Furthermore, a mutation in EGFR gene renders cancer 
cells hypersensitive to the action of coagulation proteins, such as TF, which is ultimately responsible 
for creating a favourable microenvironment for tumour growth (106). These data confirm the 
existence of a symbiotic relationship between cancer and thrombosis, where cancer cells support clot 
formation, and in turn, clotting proteins support cancer growth and dissemination (79).  
Other prothrombotic abnormalities observed in cancer patients may be related to the pathogenesis of 
cancer-associated hypercoagulability. For instance, an increase in plasma levels of von Willebrand 
20 
 
factor and factor VIII, as well as a reduction in protein S were reported in multiple myeloma patients 
(107, 108). Furthermore, prostate cancer cells express long chain polyphosphates on their surface, 
which one study showed can initiate coagulation through a factor XII-dependent pathway (109).  
 
1.6.2 Inhibition of fibrinolytic activity 
In addition to the induction of fibrin clots, cancer can also result in an inhibition of fibrinolysis.  
Tumour cells can express plasminogen activator inhibitor-1 (PAI-1), which is a major inhibitor of 
plasminogen activation by tissue-type plasminogen activator and therefore is an inhibitor of fibrin clot 
degradation (110). Elevated levels of PAI-1 were reported in individuals with different cancers, 
including ovarian cancer and multiple myeloma (111, 112). In addition, PAI-1 mRNA was  detected  
in  endothelial  cells  originating from  the tumours in patients with colorectal cancer (113).  
 
1.6.3 Induction of inflammatory responses 
Malignant cells can also secrete a variety of cytokines including interleukin (IL)-1β, tumour necrosis 
factor-α and vascular endothelial growth factor (VEGF) (114). These cytokines can in turn induce TF 
production by vascular endothelial cells, downregulate thrombomodulin expression, promote PAI-1 
synthesis and increase endothelial cell expression of heterocellular adhesion molecules (87). The 
inflammatory response to cancer or chemotherapy can also result in the formation of neutrophil 
extracellular  traps (NETs), which are scaffolds of chromatin fibres lined with antimicrobial proteins 
(115). The formation of NETs (i.e. NETosis) was originally described as part of the innate immune 
system, in which the presence of pathogens can induce neutrophil granulocytes to release these 
extracellular traps that can capture and kill microbes (116). However, NETs are also found within 
DVTs and have prothrombotic effects (116, 117). In addition, tumours can secrete granulocyte colony 
stimulating factor (CGSF), a cytokine that can contribute to cancer-associated thrombosis by 
systemically priming neutrophils toward NETosis (117). In vitro co-localisation of neutrophils with 
activated endothelial cells (a proinflammatory and procoagulant state of endothelial cells associated 
with decreased vascular integrity and increased expression of leukocyte adhesion molecules) results in 
NETosis, partly through the action of cytokines (118). NETs, in turn, promote fibrin formation 
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through stimulating platelet adhesion and factor XII activation, as well as inducing endothelial cell 
death (118-120).  
 
Figure 4: Molecular activators of coagulation in cancer. Coagulation activation in cancer-
associated thrombosis may be explained by contributions from both the tissue factor (‘extrinsic’) and 
FXII-dependent (‘intrinsic’) pathways. Tissue factor–bearing microvesicles may be released into the 
circulation by various tumour types and promote thrombin generation and ultimately thrombosis. 
FXII may be activated in vivo by a variety of negatively charged molecules. These could include 
phosphatidylserine (e.g. on microvesicles), glycosaminoglycans, polyphosphate, collagen, nucleic 
acids, and mis-folded proteins. Activation of the contact system in cancer would exacerbate the 
generation of thrombin, providing accompanying thrombotic risk. 
 
 
 
TF: tissue factor; PS: phosphatidylserine; MV: microvesicles; RBCs: red blood cells; WBCs: white blood cells; 
PLTs: platelets; PK: pre-kallikrein; KAL: Kallicrein; HK: High molecular weight kininogen.  
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1.7 Microvesicles (MVs) 
Microvesicles (MVs) or microparticles (also referred to as shedding vesicles, ectosomes) can range in 
size from 0.1 to 1.0 µm and include all structures created through budding and fission directly from 
the plasma membrane (121, 122). MVs are constitutively released from the surface of cells, and their 
formation can be upregulated by cellular activation and apoptosis. Physiologically, plasma 
membranes contain various types of phospholipids. Although uncharged phospholipids are mainly 
present in the outer leaflet of the membrane bilayer, the inner leaflet contains negatively charged 
aminophospholipids such as phosphatidylserine (PS). During cells activation or apoptosis, the normal 
lipid bilayer undergoes an alteration by “flipping” internal PS to the external surface. As a result, PS 
exposing MVs can be released from cells. The membrane composition of MVs reflects their cellular 
origins. MVs contain functional cytoadhesion proteins, bioactive phospholipids, cytoplasmic 
components, and various antigens that are characteristic of the state of the originating cell and the 
type of stimuli (122-125). Increasing evidences point to elevated levels of different phenotypes of 
MVs in patients with VTE, suggesting that MVs may play an important role in the pathophysiology of 
VTE (122, 125-127). The role of MVs in thrombogenesis can be summarized, based on previous 
studies, in these subsequent ways (128): (i) the exposure of PS and the vehiculation of TF, and (ii) 
MV-induced intercellular communication by cross-talk between inflammation and coagulation. 
Undoubtedly, the functional interplay among endothelial cells, platelets, inflammatory cells and MVs 
plays a vital role in VTE.  
 
1.7.1 Procoagulant properties of MVs: the exposure of PS and the vehiculation of TF  
Perhaps the best established property of MVs is their ability to promote coagulation (Figure 5), which 
is largely linked to their physical characteristics with two specific surface features (122, 124). First, 
the above mentioned externalization of anionic phospholipids (predominantly PS) promotes the 
interaction with clotting proteins cationic domains, allowing the subsequent assembly of coagulation 
factors (Va, VIII, IXa) and ultimately thrombin formation. The externalization of PS is believed to be 
a property of all types of MVs and is a strong promoter of coagulation, thus the optimal thrombin 
generation and efficient haemostasis. Interestingly, it has been estimated that a platelet-derived MV 
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generated ex vivo has a 50- to 100-fold higher procoagulant activity than the same blubbing area on 
an activated platelet membrane (129), which may explain the potential thrombogenicity of MVs. 
Secondly, some populations of MVs have been shown to display TF on their surface. TF has a high 
affinity for FVII/FVIIa, and therefore circulating TF-MVs readily binding FVII/FVIIa, can trigger the 
initiation of coagulation via the extrinsic pathway (122). The presence of TF on MVs dramatically 
increases their procoagulant activity, especially since PS boosts the procoagulant activity of TF and 
contributes to the propagation of the coagulation cascade. It is well known that activated monocytes 
and tumour cells are the primary sources of TF-bearing MVs in the bloodstream, however TF has 
been identified also on leukocyte MVs, endothelial MVs and platelet MVs (130-133). Platelets and 
red blood cells produce PS- and PS+MVs, whereas activated monocytes and tumour cells release 
highly procoagulant PS+TF+MVs (134). Moreover, since the density of active TF on MVs is higher 
than that on their parental cells (135), the hypothesis that MVs are effective products made in 
response to a changing environment and that MVs formation is not an entirely random process has 
been reinforced.  
 
1.7.2 Procoagulant properties of MVs: new mechanisms 
More recent data showed that MVs not only propagate coagulation by exposing PS but also initiate 
thrombin generation independently of TF and the extrinsic pathway (109, 125). In particular, platelet 
and erythrocyte-derived MVs have been shown to initiate and support thrombin generation through 
the intrinsic pathway in a FXII-dependent manner (136). In addition, erythrocyte-derived MVs may 
be also capable of promoting coagulation in a FXI-dependent manner as shown in sickle cell disease 
and in blood units (137, 138). These findings shed new light on the procoagulant properties of MVs 
and their possible hypercoagulable impact.  
 
1.7.3 Procoagulant properties of MVs: regulation of coagulation and fibrinolysis 
Apart from their well-known procoagulant activities, evidence exists regarding their ability to regulate 
coagulation - through anticoagulant antigens - and fibrinolysis. MVs have been proven to harbour 
functionally active tissue factor pathway inhibitor (TFPI) on their membrane (125, 126), and support 
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activated protein C and protein S mediated regulation of coagulation (139-141), well-known 
physiological anticoagulant pathways. Moreover, it has recently been demonstrated that MVs may 
also expose fibrinolytic properties and support plasmin generation (142, 143). These more recent 
discoveries open a new scenario where it is likely that the balance between MVs pro- and 
anticoagulant properties ultimately determines their net effect in haemostasis and thrombosis.  
 
Figure 5: Procoagulant and anticoagulant properties of microvesicles. The best established 
property of MVs is their ability to promote coagulation, which is largely linked to their physical 
characteristics: the externalization of anionic phospholipids (predominantly phosphatidylserine [PS]) 
promotes the interaction with clotting proteins cationic domains, and ultimately thrombin formation. 
Additionally, some populations of MVs have been shown to display TF on their surface and therefore 
can trigger the initiation of coagulation via the extrinsic pathway. Moreover, new mechanisms have 
been recently described. These findings support the evidence that MVs appear also able to activate the 
intrinsic pathway. Evidence exists also regarding their ability to regulate coagulation through 
anticoagulant antigens. MVs have been proven to harbor functionally active tissue factor pathway 
inhibitor (TFPI) on their membrane, and support activated protein C mediated regulation of 
coagulation.  
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1.7.4 MV-induced intercellular communication by cross-talk between inflammation and 
coagulation 
Recent studies suggest that MVs are significant mediators of intercellular communication under 
physiologic and pathologic conditions (121, 144). MVs contain antigens from their cell of origin and 
can transfer these surface molecules to other cell types and organs. The binding of MV surface 
antigens to their specific counter receptor may activate intracellular signalling pathways. 
Inflammation and haemostasis share an interactive relationship because they are linked through 
common activation pathways and feedback regulation systems. Emerging evidences support the idea 
that MVs may play a role in cross-talk between inflammation and coagulation because MVs, both 
from endothelial cells and platelets, have been shown to function as vectors for many inflammatory 
mediators (145). In vitro experiments have demonstrated that endothelium-derived MVs promote and 
stabilize platelet aggregates by bearing ultra large von Willebrand factor and that oxidized 
phospholipids in endothelium-derived MVs may be particularly active in mediating both monocytes 
adherence to endothelial cells and the activation of neutrophils. These findings suggest that the events 
surrounding the release of endothelium-derived MVs and its subsequent binding to monocytes might 
be involved in thrombogenesis (146). Moreover, MVs derived from leukocytes bear P-selectin 
glycoprotein ligand-1 (PSGL-1), which interacts with P-selectin, a well-known endothelial cell 
receptor. The interaction between PSGL-1 and P-selectin, and specifically the binding of leukocyte-
derived MVs to the activated endothelium, is involved in thrombogenesis, as recently demonstrated 
(147). Leukocyte-derived MVs also contribute to the development of thrombi through the recruitment 
of platelets and the accumulation of TF (124, 148). Finally, a series of in vitro studies demonstrated 
that MVs released by aggregating platelets may facilitate platelets and endothelial cells activation via 
the transcellular delivery of arachidonic acid or other mediators (145). It has also been suggested that 
MVs shed by leukocytes stimulate cytokines release and the induction of TF in endothelial cells by 
activating a signalling pathway which may lead to an increased proinflammatory and procoagulant 
activity. Other mechanisms contributing to the regulation of MV procoagulant properties rely on the 
balance between TNF-α and anti-inflammatory cytokines, such as interleukin (IL)-10. Indeed, 
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endogenous IL-10 was recently reported to downregulate TF vehiculation in monocytes and TF-
bearing MVs release, impeding thrombin generation (128, 144, 148). 
 
Table 9. Overall microvesicles potential functions in coagulation, fibrinolysis and inflammation. 
Function Mechanism involved MV subtype 
Procoagulant - Phosphatidylserine (PS) 
exposure 
 
- Tissue factor (TF) exposure 
 
- Intrinsic pathway activation 
(FXII and/or FXI) 
Platelet MVs – Monocyte MVs – Erythrocyte 
MVs – Endothelial MVs 
 
Platelet MVs – Monocyte MVs – Endothelial 
MVs – tumour MVs 
 
Platelet MVs – Erythrocyte MVs 
Anticoagulant - TF pathway inhibitor (TFPI) 
- Protein C pathway (TM and 
EPCR) 
Monocyte MVs – Endothelial MVs – tumour 
MVs 
Monocyte MVs – Endothelial MVs 
Fibrinolytic - tPA 
 
- uPA/u-PAR 
Endothelial MVs 
 
Monocyte MVs – Endothelial MVs – tumour 
MVs 
Anti-fibrinolytic - PAI-1 Platelet MVs – Monocyte MVs – Endothelial 
MVs 
Pro-inflammatory - ultra large vWF and oxidized 
phospholipids 
 
- P-Selectin glycoprotein ligand 1 
 
- TF 
 
- arachidonic acid 
 
- cytokines 
Endothelial MVs 
 
 
Leukocyte MVs 
 
Leukocyte MVs 
 
Platelet MVs 
 
Leukocyte MVs 
TM, thrombomodulin; EPCR, endothelial protein C receptor; t-PA, tissue plasminogen activator; u-PA(R), 
urokinase (receptor); PAI-1, plasminogen activator inhibitor type 1; vWF, von Willebrand factor. 
 
 
1.8 Microvesiscles detection  
Different methods and combinations of methods have been developed to detect and analyze MVs 
(Table 10). Appropriate sampling conditions, processing, and sample storage are essential (149). MVs 
can be directly quantified in platelet-free plasma obtained by serial centrifugation of citrated whole 
blood. Alternatively, washed MVs can be isolated from platelet-free plasma by ultracentrifugation 
before re-suspension and analysis. Flow cytometry is the most widely used method because it enables 
to analyze both quantitative and qualitative characteristics of MVs (150-152). Flow cytometry allows 
to determine size by assessment of the forward light scatter of each MV. Further accuracy is provided 
by using calibration beads of a specific diameter for comparison. Additionally, platelet-free plasma or 
MV suspensions are labeled with fluorescently conjugated monoclonal antibodies against cell-specific 
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surface antigens. Double staining of MVs allows to determine the origin/cellular source of the MVs. 
Annexin V or lactadherin binding is used to confirm the phospholipid properties of MVs, although 
some MVs do not bear these phospholipids antigens, and a variety of cell-specific antibodies have 
been employed to determine MVs subtypes (153).  
On the other hand, functional assays measure the procoagulant activity of isolated MVs. The 
advantages of functional assays include their high sensitivity, simplicity, and the use of well-defined 
reagents (124). Solid-phase capture assay consists of measuring the PS content of MVs. Briefly, 
PS+MVs are captured on an ELISA plate coated with annexin V-streptavidin and incubated with FV, 
FX, and prothrombin to form the prothrombinase complex that then promotes the cleavage of 
prothrombin to thrombin. The generated thrombin is detected using a chromogenic substrate (124, 
150). Another assay, measures the phospholipid-dependent procoagulant activity of MVs using 
phospholipid depleted substrate plasma. Factor Xa (and calcium) triggers the coagulation cascade and 
a shortening clotting time of the sample indicates an increased concentration of procoagulant 
phospholipid (154). In addition, TF dependent procoagulant activity can be assessed using a specific 
blocking antibody to TF (155-157). In particular, there are two assays to measure TF activity of MVs 
isolated from plasma by centrifugation or captured by a monoclonal antibody. The first has been used 
by a number of different laboratories, the second is quite time-consuming and has not been widely 
adopted. Finally, new techniques such as laser-induced nanotracking (158), atomic force microscopy 
(159), and dynamic light scattering have been developed (160). These advances represent exciting 
possibilities for MV analysis. 
 
1.8.1 Limitations of currently available detection methods 
The clinical research on MVs is hampered by the limitations of the currently available detection 
methods (Table 10). Firstly, pre-analytical conditions highly influence the isolation of MVs (Table 
11). For instance, isolation of MVs from blood is affected by vein puncture, tube transportation, time 
between blood collection and handling, the anticoagulant, centrifugation and washing procedures, the 
presence of lipoprotein particles and small platelets within the size range of MVs, storage, freezing 
and thawing procedures (149, 161). The only multicenter study performed by the International 
28 
 
Society on Thrombosis and Haemostasis (ISTH) Vascular Biology Standardization Subcommittee 
showed that a common pre-analytical protocol can reduce the inter-laboratory variability of flow 
cytometric enumeration of platelet-derived MVs in healthy individuals. However, the significant 
variability even when a common protocol is correctly applied remains unacceptably high for the 
clinical use of MVs (149, 162, 163). Second, it is well known that flow cytometry is the most 
common method used to determine the size and number of MVs. However this method does have 
many intrinsic drawbacks, that have been recently well reviewed (160, 161). The major points are: i) 
only a small fraction of MVs can be detected by commercial flow cytometers for polystyrene beads 
because of their detection limit (300–500 nm) and because they can resolve only particles that differ 
by approximately ≥ 280 nm in size (161); ii) quantitative size information are imperfect because they 
are obtained by comparing the scattering intensity of MVs with that of beads of known size. The 
scattering intensity, however, depends not only on size but also on shape, refractive index, and 
absorption (161). Thus, it has been postulated that flow cytometry underestimates the number of MVs 
in a sample, by up to 100–1000 times (159); iii) fluorescence threshold is also imperfect because no 
panspecific marker for total MPs exists. Annexin V should not be used to define MVs, as only a 
minority of circulating MVs expose PS and annexin V binding is highly dependent on Ca2+ 
concentrations and pre-analytical conditions (164). Indeed, there is no consensus on this point yet; iv) 
if very small MVs cannot be accurately detected, false-positive signals can arise from other non-cell-
derived particles and/or background noise (164). As far as the limitations of functional assays are 
concerned, these assays do not provide any information on MVs size, cellular source or their physical 
properties; moreover they does not take into account the purity of the sample. Optimized protocols 
(Table 11) including a combination of both quantitative and qualitative methods should be used to 
best characterize MVs in clinical studies (124, 127). However, no consensus on the best method has 
been reached so far.  
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Table 10. Methods of MVs quantification (from Burger et al. 2013 (165)) 
Protocol Quantification method Advantages Limitations 
Flow cytometry Fluorescence and light-
scattering properties MVs in 
suspension 
- Available to most 
research facilities 
 
- Rapid 
 
- Multiple antigens may be 
analyzed  MVs analyzed 
on an individual basis 
- Quantification of 100–400 
nm may be imperfect 
 
- Cell origin identification is 
antibody-dependent 
Immunoassays  Immunocapture of MVs and 
quantification based on the 
presence of surface antigen 
- Available to most 
research facilities 
- No size restrictions 
- Quantification is done in 
bulk 
- Quantifies based on a 
single antigen 
- Does not allow for size 
determination 
Functional assays MVs procoagulant or 
prothrombinase activity  
- Available to most 
research facilities  
 
- Provides an indication of 
biological activity 
- Quantification is done in 
bulk 
 
- Measures only a single 
biological activity  
 
- Does not allow for size 
determination 
Atomic force 
microscopy 
Cantilever is used to scan 
the MVs surface and tip 
displacement is related to 
surface properties 
- Allows for very accurate 
MVs sizing  
 
- Allows for 3D view of 
MV structure 
 
- May be used for 
quantification 
- Determination of cell 
origin requires development 
of specialized antibody-
coated surfaces 
 
- Not conducive to large 
sample numbers 
Nanoparticle tracking 
analysis 
MVs are visualized by light 
microscopy and light 
scattering is observed; 
Brownian motion of 
individual particles is 
tracked by video 
- Clear idea of MV size 
 
- Allows for quantification 
- Utility of assay for 
quantification is unclear 
 
- Non-universal technology 
 
- May be time-consuming 
 
Table 11. Overview of major challenges related to flow cytometric analysis of MVs (from 
Mooberry et al. 2015 (150)).  
Pre-Analytical Analytical/Technical 
•  Method of blood collection 
– Tourniquet use 
– Needle diameter 
– Type of anticoagulant 
• Flow cytometer 
– Intrinsic resolution capabilities 
 
•  Sample processing 
– Sample type (whole blood, plasma, isolated MPs) 
– Time to sample preparation 
– Centrifugation protocol 
– “Micro-clot” formation 
• Size gating 
– Beads vs biologicals 
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• Sample handling and storage 
– Sample transportation/agitation 
– Fresh vs freeze/thaw 
• Fluorescence gating 
– Proper use of isotype controls (ITCs) 
– Detection of dimly expressed antigens 
– Titration of antibodies and ITCs 
– Fluorochrome aggregates 
 • MP enumeration 
– Use of counting beads 
– “Swarm effect” 
 
1.9 Microvesicles and cancer  
Dvorak et al. (166) first proposed a relationship between tumour-derived MVs and thrombosis. The 
authors stated that shed vesicles carry procoagulant activity that can account for the activation of the 
clotting system and the fibrin deposition associated with these and many other types of malignancy in 
animals and humans. Subsequent studies showed that the procoagulant activity of the tumour-derived 
MVs was a result of the presence of TF (96, 134, 167-169). Many types of cancer cells express TF 
and release TF+MVs (96). Furthermore, circulating TF+MVs can be detected in patients with a 
variety of cancers, including pancreatic, lung, gastric, breast, and brain (169-173). Table 12 
summarizes studies evaluating the association between circulating MVs and VTE in patients with 
cancer. It is likely that these TF+MVs are released from the tumour. For instance, one study in 
patients with pancreatic cancer found that the TF+MVs co-expressed the epithelial tumour antigen 
MUC-1 and that pancreatectomy dramatically reduced the level of TF+MVs (173). The majority of 
studies have examined the relationship between TF+MVs and VTE in patients with pancreatic, brain, 
colorectal, or lung cancer because these patients have the highest rates of VTE (96). TF+MVs were 
detected in all these cancers but patients with pancreatic cancer were found to have the highest levels 
of MV TF activity (170). One possible explanation for this is that the endocrine function of the 
pancreas provides an easy route for transporting TF+MVs from the tumour into the blood. A 
longitudinal study with 11 pancreatic cancer patients found a time-dependent elevation of MV-TF 
activity that proceeded to VTE in 2 patients (98). Several other prospective studies found an 
association between MV-TF activity in patients with pancreatic cancer but not in patients with lung, 
gastric, colorectal, ovarian, or brain cancer (170, 172, 174). There was also a strong association 
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between MV-TF activity and mortality in patients with pancreatic cancer (170, 174). Overall, these 
studies suggest that TF+MVs contribute to VTE in pancreatic cancer and may be a useful biomarker 
for assessing the risk of VTE in these patients. It is likely that TF+MVs contribute to VTE in other 
types of cancer, but the current studies are too small and the current assays are not sensitive or 
specific enough to reveal a relationship between TF+MVs and VTE (134). Further development of 
TF+MV assays is needed before they can be used clinically.  
In conclusion, a definitive link between TF+MVs and the development of clinical VTE in cancer has 
yet to be established and remains somewhat debated in view of conflicting evidence (175). 
Differences in association could be due to varying levels of TF encryption and participation of TF in 
non-coagulant activities, such as signalling of the TF-FVIIa complex via protease-activated receptor 2 
(PAR2) (176). The exact contribution of TF+MVs to the development of VTE may therefore be 
highly variable between tumour types, and the association in pancreatic cancer may reflect the high 
level TF expression relative to other cancer types and/or the late stage of disease presentation (175). 
Interestingly, while around 80% pancreatic cancer patients show increased TF levels, fewer than 30% 
of these patients are found to develop thrombosis (177), indicating that elevated TF+MV levels in 
isolation do not unequivocally trigger thrombosis, and raising the interesting question of why/when 
the clinically recorded thrombosis does occur.  
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Table 12. Studies evaluating the role of circulating microvesicles (MVs) as biomarkers for 
venous thromboembolism (VTE) occurrence in cancer. 
 
Study  Patients without 
VTE/with VTE 
at follow-up 
Follow-up Method MVs detected Results 
[VTE risk] 
van Doormaal 
2012 (178) 
 
Cancer without 
VTE at study entry 
43/5 6 months FCM and 
Functional 
assay 
PS+ 
PMV 
TF+MV antigen 
TF+MV activity 
- 
- 
- 
↑ 
Thaler 2011 
(179)
 
Solid and 
haematological 
cancer  
728/53 2 years Functional 
assay 
PS+ - 
Campello 
2011 (169) 
Solid cancer with 
and without VTE 
30/30 n/a FCM PS+ 
PMV 
EMV 
TF+MV 
↑ 
↑ 
↑ 
↑ 
Zwicker 2009 
(171)
 
 
Cancer without 
VTE 
60/5 1 year Impedance 
FCM 
TF+MV ↑ 
OR 3.72  
[95% CI 1.18–11.76] 
 
Khorana 
2008 (172) 
 
Locally advanced 
or metastatic 
pancreatic cancer 
11/2 Every 4 
weeks for 
20 weeks 
Functional 
assay 
TF+MV 
TF antigen (ELISA) 
↑ 
↑ 
Bharthuar 
2010 (174) 
Pancreatic-biliary 
cancer 
117/52 
(retrospective) 
- Functional 
assay 
TF+MV activity ↑ 
OR 1.4  
[95% CI 1.1-1.6] 
Sartori 2013 
(180)
 
Glioblastoma 
multiforme 
61/11 7 months FCM TF+MV ↑ 
RR 4.17  
[95% CI 1.57–11.03] 
Auwerda 2011 
(181)
 
Multiple myeloma 
before 
chemotherapy 
122/15 not 
specified 
Functional 
assay 
TF+MV activity  
- 
Thaler 2012 
(170)
 
Cancer without 
VTE at study entry 
299 (48 
pancreatic)/49 
(12 pancreatic) 
2 years Functional 
assay 
TF+MV activity 
chromogenic and 
kinetic assay 
 
- 
HR 1.5  
[95% CI 1.0–2.4]* 
 
*Association between VTE and TF+MV activity in pancreatic cancer using chromogenic endpoint assay. 
PS: phosphatidylserine, PMV: platelet-derived MVs, TF: tissue factor, FCM: flow-cytometry.  
  
33 
 
2. Aim of the study 
Given the multifactorial genesis of hypercoagulability, the need to find clinically meaningful markers 
able to describe the thrombotic profile and the lack of studies assessing the longitudinal fluctuations 
of hypercoagulability-associated VTE biomarkers in cancer patients, we conducted a longitudinal 
cohort study to evaluate the trend of several coagulation parameters in patients with gastro-intestinal 
cancer with particular focus on tumour-derived MVs and TF+MVs.  
Our primary outcome was the description of coagulation fluctuations over a 6-month period following 
cancer diagnosis and the secondary outcomes were the association between coagulation parameters 
and clinical outcomes.  
Clinical outcomes considered were: surgical radicality (complete-incomplete), disease severity 
(localized-advanced), and VTE occurrence.  
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3. Patients and Methods 
This was a longitudinal cohort study conducted between September 2015 and September 2017 at the 
Thrombotic and Haemorrhagic Diseases Unit and General Surgery of the Padua University Hospital. 
The study was approved by the Institutional Review Board (ref. 4022/AO/16) of the Padua University 
Hospital and all the participants signed an institutional review board-approved consent form.  
 
3.1 Patients 
Patients with a new diagnosis of gastro-intestinal cancer who underwent surgery at the General 
Surgery Department of Padua University Hospital were consecutively enrolled from September 2015. 
The enrolment of patients was completed on January 2017. 
Inclusion criteria: 
- Newly diagnosed esophageal, gastric, colon or pancreatic cancer with surgical indications  
- Age > 18 years 
- Signed informed consent 
Exclusion criteria:  
- progression of previous diagnosed cancer after complete or partial remission 
- severe liver or renal failure 
- low life expectancy (i.e. Karnofsky Performance Status <60%)(182) 
- venous or arterial thromboembolism within the past 3 months 
- pregnancy/puerperium 
- overt/recent bacterial or viral infection (within the past 2 months) 
Baseline demographic and clinical data regarding age, sex, body mass index [BMI], blood group, past 
medical and surgical history, history of VTE, recent anticoagulant/antithrombotic therapy, 
antithrombotic prophylactic therapy, and preoperative chemo-radiotherapy were collected.  
General laboratory determinations, routinely assessed pre-operatively, including haemogram, C-
reactive protein (CRP), traditional coagulation tests (prothrombin time (PT) and activated partial 
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thromboplastin time (aPTT) and levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 
19-9 (CA19-9) were recorded.  
Moreover, clinical variables and cancer-specific variables were prospectively collected.  
In particular, we recorded: 
- peri/post-operative surgical complications  
- possible transfusion therapy  
- surgical radicality 
- histology (including pathological tumour-node-methastasis [pTNM] and cancer stage (183))  
- possible adjuvant chemo-radiotherapy programme  
The Khorana Risk Score (66) was calculated for each patient, and the data for the calculation 
correspond to clinical data obtained within 1 month of recruitment, including blood counts.  
All patients received antithrombotic prophylaxis with graduated elastic stockings and low-molecular 
weight heparin for 30 days after surgery.  
 
3.2 Blood sampling for coagulation tests and pre-analytical conditions 
Venous fasted blood samples (12 mL) were collected into 3.2% sodium citrate with a light tourniquet, 
using a butterfly device with 21-gauge needle without venostasis (the first few ml discarded to avoid 
the contact phase activation). Platelet-free plasma (PFP) was prepared within 2 hours following the 
drawing by double centrifugation (2 x 15 min at 2,500 g) at room temperature. Aliquots of plasma 
were immediately frozen and then stored at -80°C until use.  
Blood samples for coagulation tests were collected: 
- baseline (after the enrollment) the day before surgery 
- 7 days post-surgery  
- 1 month post-surgery 
- 6 months post-surgery 
The baseline blood sample was collected before the start of thromboprophylaxis with low-molecular 
weight. The 7 days and 1 month post-surgery blood sample were collected before low-molecular 
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heparin administration (at least 24 hours wash-out), in order to avoid the interference of heparin with 
coagulation parameters measurements.    
Longitudinal samples were collected during follow-up visits at the Ambulatory of the Thrombotic and 
Haemorrhagic Diseases Unit, and tumour-related clinical history and clinical outcomes were also re-
evaluated. For pre-analytical and analytical analysis, we followed the recent standardization protocol 
by the Scientific Collaborative Workshop of the International Society of Thrombosis and Haemostasis 
(ISTH) (163). 
 
3.3 Coagulation parameters  
3.3.1 Whole blood Thromboelastometry 
Viscoelastic clotting measures were performed on whole blood by ROTEM® (Tem International 
GmbH, Munich, Germany) test according to the manufacturer’s protocol (184). In particular, blood 
was incubated at 37 °C in a heated cup. Within the cup is suspended a pin connected to an optical 
detector system. The cup and pin are oscillated relative to each other through an angle of 4°45”. As 
fibrin forms between the cup and pin, the transmitted impedance of the rotation of the pin is detected 
at the pin and a trace generated (Figure 7). All analyses were performed within 2 hours after blood 
collection and, once initiated, the blood coagulation was allowed to run 60 min. Extrinsic coagulation 
cascade was studied with EXTEM test (ex-TEM®; Tem International GmbH) and intrinsic 
coagulation cascade was studied with INTEM test (in-TEM®; Tem International GmbH). The 
influence of fibrinogen on clot firmness was estimated with the platelet-inactivating FIBTEM test 
(fib-TEM®; Tem International GmbH). The following ROTEM parameters were analysed (Table 13):  
i) Clotting time (CT, sec), corresponding to the time from the beginning of the coagulation analysis 
until an increase in amplitude of 2mm. The CT reflects the initiation phase of the clotting process;  
ii) Clot Formation Time (CFT, sec), the time between an increase in amplitude of thromboelastogram 
from 2 to 20 mm. The CFT measures of the propagation phase of clot formation;  
iii) Maximum Clot Firmness (MCF, mm), the maximum amplitude in mm reached in 
thromboelastogram. It correlates with the platelet count and function as well as with the concentration 
of fibrinogen. The MCF quantifies the strength of the established whole blood coagulum;  
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iv) Maximum Lysis (ML, %), the percentage of lost clot stability (relative to MCF, in %) when the 
test has been stopped.  
 
Table 13. Summary of the thromboelastometry variables measured.  
 
Parameters Description Meaning Correlation  to  
conventional 
tests 
Clotting time, CT (sec) Time from start to 
2mm above  baseline 
- Initiation of thrombin 
generation and clot 
polymerization.  
- Expression of  
coagulation factors 
activity 
PT – aPTT 
Clotting formation time, 
CFT (sec) 
Time from start of 
clotting to amplitude 
of 20 mm 
- Rate of clot 
formation 
- Fibrin 
polymerization  
and cross-linking with  
platelet interaction 
Fibrinogen  
concentration,  
platelet count 
Maximum Clot Firmness, 
MCF (sec) 
Maximum strength Stabilization of clot by  
platelets and FXIII 
Fibrinogen  
concentration,  
platelet count 
Maximum Lysis, ML (%) Decrease of clot 
firmness after MCF 
Degree of fibrinolysis  
after a given amount 
of time 
 
 
Figure 6. Graphical representation of thromboelastometry coagulation and lysis parameters 
considered in the study. CT: clotting time (sec); CFT: clotting formation time (sec); MCF: 
maximum clot firmness (mm); ML: maximum lysis (%). 
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3.3.2 Procoagulant factors and fibrinolysis 
  
Factor VIII and fibrinogen activity were measured using fresh unfrozen plasma on a BCS-XP 
Analyser (Siemens Healthcare Diagnostics, Marburg, Germany).   
D-dimer levels were measured with a quantitative latex immunoassay (HemosIL HS D-dimer 500; 
Diagnostica Stago, Asniers, France) on an ACL TOP® Family Sistems (Diagnostica Stago).  
A commercially available enzyme-linked immunosorbent assays (ELISA) was used to measure 
Plasminogen activator inhibitor-1 antigen (PAI-1:Ag) (ZYMUTEST PAI-1 Antigen, HYPHEN 
BioMed, Neuville-sur-Oise, France).  
 
3.3.3 Hereditary Thrombophilia 
Genomic DNA was extracted from whole blood using an automated method (MagCore Extracted 
System H16, RBC Bioscience, Mew Taipei City, Taiwan).  Detection and genotyping for factor V 
Leiden R506Q (mutation rs6025) and prothrombin G20210A (mutation rs1799963) was performed 
using commercially available kits for Real-Time PCR (polymerase chain reaction). Real Quality RS-
Factor V Leiden (AB Analitica, Padova, Italy) was used to detect factor V Leiden and Real Quality 
RS Fator II G20210A (AB Analitica, Padova, Italy) to detect prothrombin mutation.  
 
3.3.4 Contact activation pathway 
A home-made capture ELISA was used to quantify contact system proteins in order to evaluate the 
role of the contact system activation in cancer (185). ELISAs for enzyme-inhibitor complexes may 
serve as biomarkers for recent and/or ongoing contact system activation due to their reduced 
circulating half-life (185, 186). The levels of FXIa, FXIIa and kallikrein in complex with C1-esterase 
inhibitor (C1INH) were measured in plasma with ELISAs. Briefly, plates were coated overnight at 
room temperature with 100 µL of 10 µg/mL MoAb KOK-12, which binds complexed and inactivated 
C1-inhibitor. The plates were then incubated with plasma samples diluted in PBS-milk 2%. FXIIa-, 
FXIa- or kallikrein-C1-inhibitor complexes were prepared by incubating 10 µmol/L C1-inhibitor 
(Behringwerke AG, Marburg, Germany) overnight at 37°C with 1.4 µmol/L FXIIa, 2.7 ·mol/L FXIa, 
or 2.3 µmol/L kallikrein, respectively. FXIIa-C1INH complexes were detected by incubation for 1 
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hour of the plates with the biotinylated MoAb F3, FXIa-C1INH by incubation with biotinylated 
MoAb XI-5 and kallikrein-C1-inhibitor complexes by incubation with biotinylated MoAb K15, each 
diluted in PBS containing milk 3% and normal mouse serum 1%. Next, the plates were incubated for 
30 minutes with a 1:10,000 dilution of polymerized horseradish peroxidase bound to streptavidin 
(poly-HRP; CLB) in PBS-milk 2%. Absorbance was read at 450 nm on a microplate reader. Kaolin-
activated plasma was used as reference (187).  
 
3.4 Circulating microvesicles 
3.4.1 MV-TF activity 
For the MV-associated TF activity measurement, MVs were pelleted from 200 µl of PFP by 
centrifugation at 20,000 g for 30 min at 4 °C, washed twice with HBSA (120mM NaCl, 20mM 
HEPES, 1mg/mL BSA, pH 7.4), and re-suspended in 200 µl of HBSA. 50 µl aliquots were then added 
to duplicate wells of a 96-well plate and samples were incubated with either a neutralizing antibody to 
human TF (hTF1; 4 µg/ml) (1 µl) or an isotype-matched murine monoclonal IgG antibody (4 µg/ml) 
(1 µl) for 15 min at room temperature. Next, 50 µl of HBSA containing 2 nM FVIIa, 300 nM FX and 
10 mMCaCl2 were added to each sample and the mixture incubated for 2 h at 37°C. FXa generation 
was stopped by 25 µl of 25 mM EDTA buffer and 25 µL of the chromogenic substrate S2765 (1.2 
mM) (Chromogenix S-2765) was added. Absorbance at 405 nm was measured using a microplate 
reader for 30 min every 30 sec.  TF activity was calculated by reference to a standard curve generated 
using Innovin™, a re-lipidated recombinant human TF. The TF-dependent FXa generation (optical 
density [OD]) was determined by subtracting the amount of FXa generated in the presence of hTF1 
from the amount of FXa generated in the presence of the control antibody, and converted to TF 
concentration (pg/mL) by reference to the standard curve (172, 174, 188).  
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3.4.2 Flow Cytometric Analysis of Microvesicles 
Flow cytometry was performed using a CytoFLEX flow cytometer (Beckman Coulter). The 
CytoFLEX is equipped with a more sensitive Side Scatter (SSC) resulting in higher particle resolution 
compared to the Forward Scatter (FSC). The CytoFLEX has a three laser pathway: red laser (638 nm) 
– blue laser (488 nm) – violet laser (405 nm). This means that normally the blue laser serves as the 
triggering laser, the red laser gets a positive and the violet laser a negative time delay. To standardize 
the instrument to detect MVs, standard filter configuration was changed so that the SSC from the 405 
nm violet laser (VSSC) was used as trigger signal to discriminate the noise instead of the normally 
used 488 nm FSC. When the VSSC was used as a trigger signal the noise was significant lower in 
comparison to the 488 nm SSC when beads were used as standardization reference (189) (Figure 8). 
For MV size calibration of the flow cytometer fluorescent polystyrene beads (Megamix FSC & SSC 
Plus, BioCytex, Marseille, France) were used in sizes of 0.1, 0.16, 0.2, 0.24, 0.3, 0.5, and 0.9 µm. 
VSSC and FL1 channel gain were set to visualize the beads (Figure 8, panel A and B). Megamix bead 
solution was gated excluding the background noise (due to the solution itself). After turning the set in 
VSSC and FSC, a rectangular gate was set between the 0.1 mm and 0.9 µm bead populations and 
defined as MV gate (Figure 8, panel C). According to the diameter of beads three gates were created, 
in order to detect big MVs (0.5-0.9 µm), small MVs (0.2-0.3 µm), and nano MVs (0.1-0.2 µm) (Figure 
8, panel D). A suggested by Wisgrill et al. (189) the run was performed with a maximum event rate up 
to 2,000 events/sec at the lowest flow rate (10 mL/min).  
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Figure 8. Microvesicles gate creation with fluorescent polystyrene beads in sizes of 0.1, 0.16, 0.2, 
0.24, 0.3, 0.5, and 0.9 µm. (A-D) Fluorescence polystyrene beads of different sizes were used to 
determine the MV gate between the 0.1 μm and 0.9 μm bead peaks. 0.1 μm fluorescence beads were 
detectable using the 405 nm side scatter (VSSC).  
 
 
 
3.4.3 Microvesicles detection 
PFP was thawed in a waterbath for 5 min at 37°C and immediately processed for immunolabeling. 
PFP was analyzed only after a single freeze-thaw cycle. Prior to the staining, the antibody mixture 
was centrifuged at 20,000g for 30 minutes to remove fluorescent particles (190).  
Twenty µL of PFP was stained with 2 µL of FITC-labeled annexin V (eBiosceince, Bender 
MedSystems GmbH, Vienna, Austria) + 2 µL of PE-labeled anti-CD62E antibody (BioLegend, San 
Diego, CA) + APC-labeled anti-227 antibody (MUC-1 antigen for pancreatic and gastro-esophageal 
cancers) (BioLegend, San Diego, CA) or APC-labeled anti-326 antibody (EpCAM antigen for colon 
cancer) (BioLegend, San Diego, CA) for 15 minutes at 37°C. Parallel incubation was performed with 
isotype-matched control antibody. True MV events were defined as double positive-stained for 
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annexin and anti-CD62E and double-stained for annexin and anti-tumour antigen events (Figure 9, 
panel D). Stained PFP was then diluted 1:400 with annexin binding buffer (Bender MedSystems) 
containing recombinant Hirudin (Sigma Aldrich, St. Louis, MO) to prevent clot formation. Diluted 
binding buffer was sterile filtered through a 0.2 μm mesh to reduce background noise. MVs were 
further characterized by surface staining for following subpopulations:  
- Total annexin-positive (PS+) 
- Total annexin-negative (PS-) 
- Annexin+CD62E+ (endothalial-derived MVs) 
- Annexin+CD227+ or Annexin+CD326+ (tumour-derived MVs) 
Fluorescence measured with the respective isotype negative control antibody were subtracted in order 
to avoid unspecific signal. MVs were expressed as events/µL with the volume measurement of the 
CytoFLEX. Files were exported and data were evaluated by CytExpert (Software Version 1.2, 
Beckman Coulter).  
 
Figure 9. Microvesicles detection. Using the defined MV gate, all events positive for annexin V 
were defined as big, small or nano-MV events (Panel A-C). MV were further analysed for surface 
marker staining; double positive-stained for annexin and anti-CD62E and double-stained for annexin 
and anti-tumour antigen events were considered (Panel D).  
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3.5 Outcomes  
The primary outcome was the evaluation of coagulative parameters trend over a 6-month period 
following the diagnosis. Clinical outcomes recorded during the follow-up were: i) surgical radicality 
(i.e. complete or incomplete); ii) cancer severity (i.e. localized or advanced cancer); iii) any 
thrombotic event including superficial vein thrombosis (SVT), symptomatic or asymptomatic VTE 
(DVT and/or PE) or thrombosis in unusual sites. The secondary outcome was the association between 
the coagulative profile at the different time-points and the clinical outcomes.    
DVT/SVT was confirmed by compression ultrasound, and PE was confirmed by pulmonary computed 
tomography (CT). We considered calf vein thrombosis as distal and thrombosis in popliteal vein or 
above as proximal. Portal vein thrombosis was diagnosed by abdominal CT or splanchnic venous 
ultrasound.  
Disease progression was evaluated by total body CT, nuclear magnetic resonance (NMR) and/or PET-
CT, and tumour markers trend (CEA, CA 19-9), according to the oncologic follow-up of the patient.  
Each patient was followed for at least 6 months and for a maximum of 12 months. Clinical follow-up 
duration was calculated from enrolment to the last contact with patient (phone call or official medical 
reports). 
 
3.6 Statistical analysis 
The qualitative and quantitative variables were expressed as frequencies and median with interquartile 
range, respectively. The coagulative parameters at the different time-points were compared through 
Friedman test for non-parametric paired values with Dunn's correction for multiple comparisons. 
Non-parametric Mann–Whitney or Kruskal-Wallis tests were used to compare median coagulative 
parameters between two or more non-paired groups, respectively. Spearman correlation test was used 
to correlate laboratory parameters. The clinical outcomes were described by cumulative incidence and 
incidence rate (with 95% confidential interval [CI]). Multivariable logistic regression analysis was 
performed in order to evaluate the possible prediction role of coagulative parameters for surgical 
radicality and severity of cancer. The association between the odds of VTE and coagulative 
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parameters were evaluated. For this purpose, Cox regression multivariable analysis was performed to 
evaluate which parameters were significantly associated with VTE occurrence. Receiver operating 
characteristic (ROC) curves for cut-off levels of the parameters detected by Cox were calculated by 
considering VTE patients cases and non-VTE patients controls. Levels with sensitivity and specificity 
>80% were used as cut-off points to discriminate between high and low levels. Kaplan-Meier 
analyses were applied to compare thrombosis-free survival among groups defined by risk scores and 
log-rank tests were used to test whether differences among groups were statistically significant. 
Hazard ratios (HR) for VTE were calculated by multivariable Cox regression analyses. All the tests 
were two-tailed, and differences were considered significant at p<0.05. All the analyses were 
performed using IBM-SPSS 19.0.  
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4. Results 
 
4.1 Characteristics of the study population 
Out of 130 cancer patients consecutively admitted to the General Surgery Department of the Padua 
University Hospital with a diagnosis of gastrointestinal or pancreatic cancer during the study period, 
37 were excluded for the following reasons: i) 5 patients refused to participate; ii) 10 patients lived 
outside the Veneto Region and the follow-up was not possible; iii) 6 patients underwent surgery for 
cancer recurrence; iv) 4 patients had a Karnofsky Performance Scale <60%; v) 3 patients had severe 
liver failure; vi) 2 patients had VTE one month before the surgery; vii) 7 patients were excluded after 
the first sample because the histology did not confirm the neoplasm or was compatible with different 
peculiar neoplasms (e.g. neuroendocrine cancer, metastasis from a different site, sarcoma).  Thus, 93 
patients (25 with pancreatic cancer, 33 with colon cancer and 35 with esophagus or stomach cancer) 
were enrolled in the study. Out of 35 patients with esophageal-gastric cancer, 19 (54%) had cancer of 
esophagus or gastric cardia and 16 (46%) had gastric cancer. Figure 10 shows the flow-chart of the 
study.  
 
Figure 10. Study flow-chart: 
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The baseline characteristics of the population are reported in Table 14 categorized by cancer type. In 
particular, median age of the enrolled patients was 69, 72 and 69 years for pancreatic, colon and 
gastroesophageal cancer, respectively. There was a higher proportion of male, especially in the third 
group (p ANOVA <0.05). The BMI was similar in all three groups, with median levels of 24.2, 26 
and 24.3 Kg/m2, respectively. The non-0 blood group was the most prevalent in the population. As far 
as surgery was concerned, surgical radicality was obtained in 48% of pancreatic, 67% of colon and 
83% of gastric-esophageal cancer (p ANOVA <0.001). Pancreatic cancer was associated with a 
higher rate of surgical complications (52% vs 21% and 26% for colon and gastric cancers, 
respectively, p ANOVA <0.01) and received more blood transfusions (32%) compared to the other 
cancer subtypes (21 and 11%, respectively, p ANOVA <0.01). Surgical complications included 
wound dehiscence, anastomotic fistula, post-operative bleeding, parastomal phlegmon, and intra-
abdominal fluid collections. The histology from the surgical biopsy showed that 16% and 60% of 
pancreatic cancer had localized (stage I-IIa) and locally advanced (stage IIb-III) cancer, respectively. 
The same with respect to colon cancer was 33% and 46%, respectively. Among gastric-esophageal 
cancer, 40% had localized and 40% locally advanced disease. The proportion of metastatic cancer 
(stage IV) was similar among groups (around 20%).  60% of pancreatic and colon cancer received 
adjuvant chemotherapy after surgery vs 46% of gastric cancer. Finally, there was a higher proportion 
of patients with a high thrombotic risk, according to the Khorana score (≥3), in the pancreatic group 
(48%) vs gastric group (6%, p<0.001). None of the patients with colon cancer showed a high 
thrombotic risk profile, with 70% of them having a low risk score (0).  
 
Table 14. Baseline characteristics of the study population. 
 Pancreatic cancer 
n. 25 
Colon cancer 
n. 33 
Gastric-
esophageal cancer 
n. 35 
Age – years 69 [62-76] 72 [58.5-77.5] 69 [61-75] 
Male – n(%) 13 (52) 20 (61) 26 (74) 
BMI – Kg/m2 24.2 [21.2-25.4] 26 [22.3-28.8] 24.3 [22.2-26.6] 
Blood group – n(%) 
       - 0 blood group 
       - non 0-blood group 
 
9 (36) 
16 (64) 
 
12 (36.3) 
21 (63.6) 
 
14 (40) 
21 (60) 
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Karnofsky Performance Status - % 80 [80-90] 90 [80-90] 90 [80-90] 
Neo-adjuvant therapy – n(%) 2 (8) 6 (18) 9 (26) 
Surgical radicality – n(%)  12 (48) 22 (67) 29 (83) 
Surgical complications – n(%) 13 (52) 7 (21) 9 (26) 
Transfusions – n(%) 8 (32) 7 (21) 4 (11) 
Stage – n(%) 
     - Localized (I-IIa) 
     - Locally advanced (IIb-III) 
     - Distant metastasis (IV) 
 
4 (16) 
15 (60) 
6 (24) 
 
11 (33) 
15 (46) 
7 (21) 
 
14 (40) 
14 (40) 
7 (20) 
Histology – n(%) 
     - Adenocarcinoma 
     - Squamous carcinoma 
     - Other 
 
22 (88) 
- 
3 (12) 
 
31 (94) 
- 
2 (6) 
 
27 (77) 
8 (23) 
- 
Adjuvant therapy – n(%) 
        - platin protocols 
        - Other 
15 (60) 
3 (20) 
12 (80) 
19 (57.6) 
14 (74) 
5 (26) 
16 (46) 
10 (62.5) 
6 (37.5) 
Khorana score – n(%) 
        - High ≥ 3 
        - Intermediate 1-2 
        - Low 0 
 
12 (48) 
12 (48) 
1 (4) 
 
- 
10 (30) 
23 (70) 
 
2 (6) 
18 (51) 
15 (43) 
Variables are expressed as median and range interquartile or frequency.  
 
4.2 Clinical outcomes during the follow-up 
The median duration of the clinical follow-up was 6 months [6-8.5] for pancreatic, 8 months [7-11] 
for colon, and 6.5 months for gastric cancer [6-9.25] (Table 15).  
Within the pancreatic cancer group, the cumulative incidence of VTE was 20% [95%CI 8.8-39.13] 
over the 6-month follow-up period (Table 15). The incidence rate of VTE, considering the different 
follow-up duration for each patient (total person-time 652 months), was 9.21 [95%CI 3.37-20.4] per 
100 person-years. As for colon cancer, the cumulative VTE incidence was 12.1% [95%CI 4.8-27.3] 
over the 8-month follow-up period. Moreover, the VTE incidence rate (total person-time 717 months) 
was 6.69 [95%CI 2.13-16.2] per 100 person-years. Finally, in the subgroup of esophageal cancer 
patients, VTE occurred in 17.1% [95%CI 8.1-32.7] over the 6.5-month of follow-up period, whereas 
the VTE incidence rate (total person-time 688 months) was 10.4 [95%CI 4.24-21.7] per 100 person-
years. The median time of VTE occurrence was 2 months after surgery for pancreatic cancer and 3 
months after surgery for colon cancer. On the contrary, most of the VTE events (4 out of 6) in the 
gastric-esophageal group were post-operative, occurring in the first 15 days after surgery.  
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Disease progression was recorded in 40% of pancreatic cancer [95%CI 23.4-59.3], occurring at a 
median of 3.5 months after surgery. The proportion of disease progression among colon cancer 
patients was 21.2% [95%CI 10.7-37.7], occurring at a median of 4 months after surgery. The same 
figure for gastroesophageal cancer was 22.8% [95%CI 12.07-39.02], being diagnosed at a median of 3 
months after surgery.  
Five pancreatic cancer patients (20% [95%CI 8.8-39.13]) died during the 6-month follow-up period, 
and they died at a median of 2 months after enrollment. As for colon cancer, 2 patients died (6.06% 
[95%CI 1.02-18.6]) during the 8-month follow-up period, at a median of 5.5 months after the 
enrollment. Finally, 4 patients with esophageal-gastric patients died (11.4% [95%CI 4.5-25.9]) over 
the 6.5-month follow-up period, at a median of 2.5 months after surgery. Clinical follow-up was 
complete for the whole study population (100%) through medical/oncologic records, phone calls to 
patients and treating physicians. 
 
Table 15. Main outcomes during the follow-up 
 Pancreatic 
cancer 
n. 25 
Colon cancer 
n. 33 
Gastric-
esophageal 
cancer 
n. 35 
Total observation time – months 6 [6-8.5] 8 [7-11] 6.5 [6-9.25] 
Thromboembolic events – n(%) 
       - Superficial vein thrombosis 
       - Proximal deep vein thrombosis 
       - Distal deep vein thrombosis 
       - Pulmonary embolism 
       - Portal vein thrombosis 
       - Upper extremity deep vein thrombosis 
5 (20) 
- 
1 (20) 
- 
2 (40) 
2 (40) 
- 
4 (12) 
1 (8.3) 
1 (25) 
1 (25) 
- 
1 (25) 
- 
6 (17) 
- 
3 (50) 
1 (16.6) 
1 (16.6) 
- 
1 (16.6) 
Time of VTE occurrence from enrollment– months 2 [1.125-6.5] 3.25 [0.5-6] 0.5 [0.5-1] 
Disease progression – n(%) 10 (40) 7 (21) 8 (23) 
Time of disease progression from enrollment- months 3.5 [3-5.25] 4 [3-9] 3 [3-7] 
Death – n(%) 5 (20) 2 (6) 4 (11.4) 
Time of death from enrollment - months 2 [1-3] 5.5 [5-6] 2.5 [1.25-8.25] 
Variables are expressed as median and range interquartile or frequency.  
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4.3 Baseline laboratory and coagulative parameters  
 
Regarding blood samples, 93 patients out of 93 reached the 7 days blood draw; 90 out of 93 reached 
the 1 month follow-up visit and blood draw (one patient died of pulmonary embolism, two patients 
died of surgical complications), 80 patients reached the 6-month follow-up visit and blood draw (8 
patients died during the follow-up, 2 had a worsening of Karnofsky Performance Status and 1 refused 
blood draw). Thus, complete coagulation follow-up (6 months after diagnosis) was only available for 
79 out of 93 patients (85%) (Figure 10).  
Table 16 shows the laboratory and coagulation parameters measured in the study population at 
baseline categorized by cancer type. Generally speaking, all cancer patients showed white blood cell 
and platelet counts, PT, and aPTT within the normal range and were slightly anemic. Also, C-reactive 
protein was slightly increased in all three cancer groups. Levels of factor VIII in pancreatic cancer 
were significantly increased compared to the normal range and significantly higher compared with the 
other cancer types (p ANOVA <0.001). As far as the fibrinolytic system was concerned, both D-
Dimer and PAI-1 antigen were increased in all cancer patients, with a greater increase within the 
pancreatic cancer group. Finally, 6 patients out of the overall population (6.4%) patients were carriers 
of hereditary thrombophilia: namely one factor V Leiden carrier in the pancreatic group, one factor V 
Leiden and one prothrombin mutation in the colon group, and one factor V Leiden and two 
prothrombin mutation in the gastric subgroup.   
 
Table 16. Baseline laboratory and coagulation parameters in the study population.  
 Pancreatic cancer 
n. 25 
Colon cancer 
n. 33 
Gastric-esophageal 
cancer 
n. 35 
White blood cells – x109/L 
(r.v. 4.40-11) 
7.55 [6.32-8.79] 7.00 [5.48-8.25] 7.57 [5.79-9.91] 
Hemoglobin – g/dL 
(r.v. 13-17) 
115 [108-124] 114 [105-123] 115 [108-131] 
Platelets - x109/L 
(r.v. 150-450) 
315 [236-425] 261 [215-367] 313 [249-403] 
C-reactive protein –mg/dL 
(r.v. 0-6) 
44 [21-58] 49 [28.2-63.5] 55 [35-80] 
PT - % 
(r.v. 75-11) 
88.5 [66.7-99] 85 [70.5-102] 85 [75-95] 
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aPTT – sec 
(r.v. 22-32) 
25 [24-26] 25 [24-28] 25 [23.2-27] 
Factor VIII - % 
(r.v. 60-160) 
189 [207-185] 146 [104-199] 126 [103-156] 
Fibrinogen – mg/dL 
(r.v. 150-450) 
339 [294-468] 389 [309-544] 326 [280-421] 
D-dimer – ng/mL 
(r.v. <500) 
1001 [395-2274] 498 [349-1971] 763 [327-1215] 
PAI-1 ag – ng/mL 
(r.v. 1-10) 
14.2 [8.9-50] 12.8 [9.5-23.3] 13.2 [6.4-19.1] 
Thrombophilia – n(%)                                 
Factor V Leiden                                    
Prothrombin mutation                           
1 (4) 
1(4) 
- 
2 (6) 
1 (3) 
1 (3) 
3 (8.5) 
1 (2.8) 
2 (5.7) 
Data are expressed as median and range interquartile or frequency.  
r.v.: reference values; PT: prothrombin time; aPTT: activated partial thromboplastin time; PAI-1: plasminogen 
activator inhibitor 1.  
 
 
4.4 Baseline thromboelastometry  
 
Table 17 shows the baseline main thromboelastometric parameters measured in the study population 
categorized by cancer type. All the ROTEM® parameters were within the normal reference values 
(Table 17). Patients with pancreatic cancer showed baseline values of MCF in FIBTEM at the upper 
limit of the standard (23 mm [19-30]) and slightly increased compared with the other cancer patients. 
They also showed a mild reduction of lysis (ML= 4% [3-8]) compared to both the colon and the 
gastric subgroups.  
 
Table 17. Baseline thromboelastometric parameters in the study population.  
 Pancreatic 
cancer 
Colon cancer 
 
Gastric-esophageal 
cancer 
INTEM 
     CT – sec                                 176 [170-184] 
(r.v. 100-240) 
     CFT – sec                                 60 [45-77] 
(r.v. 30-110) 
     MCF- mm                                67 [70-72] 
(r.v. 50-72) 
 
185 [171-200] 
 
58 [44-77] 
 
      67 [73-64] 
 
181 [162-200] 
 
68.5 [52-79] 
 
65 [62-70] 
EXTEM 
     CT – sec                                   66 [55-73] 
(r.v. 38-79) 
     CFT – sec                                 60 [48-71] 
 
67 [59-75] 
 
60 [44-77] 
 
65 [59.5-71] 
 
69.5 [53-83] 
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(r.v. 34-159) 
     MCF- mm                                69 [76-64] 
(r.v. 50-72) 
     ML - %                                      4 [3-8] 
(r.v. 0-15) 
 
69 [63-76] 
 
6 [4-8.75] 
 
66 [63-71] 
 
6 [3-8.5] 
FIBTEM MCF – mm                  23 [19-30] 
(r.v. 9-25) 
20 [16-32] 18.5 [15-26.5] 
Data are expressed as median and range interquartile. 
r.v.: reference values; CT: clotting time; CFT: clotting formation time; MCF: maximum clot firmness; ML: 
maximum lysis. 
 
4.4.1 Trend of coagulative and thromboelastometry parameters during the follow-up 
The analysis for parameters trend was calculated in the 79 patients who completed the sample 
longitudinal follow-up. Overall, cancer patients showed a significant longitudinal increase of factor 
VIII activity 7 days (median [IQR] 249 [1214-300] %), 1 month (208 [157-238] %) and 6 months 
(176 [135-254] %) after surgery, compared to the baseline (140 [105-199] %, p<0.001, 0.0014, 
0.031, respectively) (Figure 11). They also showed significantly prompt increases of fibrinogen 
and D-Dimer levels 7 days after surgery with a decrease to pre-surgery levels 1 and 6 months later 
(Figure 11). Levels of PAI-1 antigen did not significantly change over the follow-up. Interestingly, 
factor VIII remained significantly higher than the baseline up to 6 months after surgery (p=0.031 
compared to baseline).  
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Figure 11. Longitudinal trend of factor VIII activity (A), fibrinogen (B), PAI-1 (C) and D-Dimer 
(D) in the overall cancer population.  
 
 
 
Data are expressed as median and interquartile range. 
P values are calculated versus baseline levels. Grey bars indicate normal ranges.  
Data are calculated in the 79 patients who completed the overall follow-up. 
 
FVIII: factor VIII; FIBRI: Fibrinogen; PAI: Plasminogen activator inhibitor-1; DD: D-Dimer; B: Baseline; 7: 7 
days; 1M: 1 month; 6M: 6 months.  
 
 
 
Regarding ROTEM® parameters, there was a significant increase of MCF in INTEM, EXTEM and 
FIBTEM 7 days after surgery (p< 0.001) in all three tests, with a slight decrease towards pre-surgery 
levels 1 month and 6 months after surgery (Figure 12). The lysis parameter (ML) did not change 
significantly during the follow-up period (Figure 12).  
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Figure 12. Longitudinal trend of ROTEM parameters (MCF and ML) in the overall cancer 
population.  
 
 
Data are expressed as median and interquartile range. 
P values are calculated versus baseline levels. Grey bars indicate normal ranges. 
Data are calculated in the 79 patients who completed the overall follow-up. 
 
MCF: Maximum Clot Firmness.  
 
 
4.5 Baseline contact activation system 
As previously mentioned, contact system activation was measured through the presence of complexes 
made of each of the three contact system factors (FXIIa – FXIa –Kallikrein) and their main inhibitor 
(C1INH - C1 esterase inhibitor). ELISAs for enzyme-inhibitor complexes may serve as biomarkers 
for recent and/or ongoing contact system activation. We found increased levels of all three complexes 
in cancer patients compared to indicative reference values calculated in a group of 10 healthy subjects 
(half males and half females) (Table 18). Particularly, we detected the highest increase in contact 
system activation in pancreatic and gastroesophageal cancer compared with colon cancer.  
 
Table 18. Baseline contact system parameters in the study population.  
 Pancreatic 
cancer 
Colon cancer 
 
Gastric-esophageal 
cancer 
FXIIa-C1INH – nM             2.51 [1.91-4.86] 
(r.v. 0.176-0.32) 
2.21 [1.02-3.40] 2.55 [1.80-4.22] 
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FXIa-C1INH – nM              0.36 [0.14-0.67] 
(r.v. 0.131-0.206) 
0.21 [0.083-0.56] 0.39 [0.13-0.66] 
Kallikrein-C1INH – nM      1.81 [0.90-3.55] 
(r.v. 0.133-0.314) 
1.70 [1.20-3.24] 2.31 [1.15-5.24] 
Data are expressed as median and range interquartile. 
r.v.: reference values; FXIIa: activated Factor XII; FXIa: activated Factor XI; C1INH: C1 esterase inhibitor. 
Indicative reference values were calculated in a group of 10 healthy volunteers (half male).  
 
4.5.1 Trend of contact system parameters over the follow-up 
The trend of contact system activation showed a slight increase over time of FXIIa-C1INH 
complex which became significantly higher than baseline 6 months after surgery (p=0.046). FXIa-
C1INH slightly increased over time without reaching statistical significance compared to baseline.   
Finally, we observed a non-significant decrease of Kallikrein-C1INH complex during the follow-
up period (Figure 13). One possible explanation for the increase of FXIIa-C1INH complex 6 
months after surgery could be related to the chemotherapy. In fact, we compared levels of contact 
system complexes in patients undergoing chemotherapy versus patients who did not at the 6-month 
time-point. Interestingly, cancer patients in chemotherapy showed significantly higher levels of 
Kallikrein-C1INH (1.668 nM [0.69-4.072]) than patients without chemotherapy (1.248 nM [0.722-
2.11], p=0.034) (Figure 14, panel C). They also showed a trend of higher levels of FXIIa-C1INH 
(7.363 nM [2.73-10.81]) and FXIa-C1INH (0.38 nM [0.22-0.50]) than patients without 
chemotherapy (5.7 nM [5.70-1.89] and 0.351 nM [0.237-0.51], respectively). However, the 
differences were not statistically significant (Figure 14).  
 
Figure 13. Longitudinal trend of FXIIa-C1INH (A), FXIa-C1INH (B) and Kallikrein-C1INH 
(C) in the overall cancer population.  
 
 
Data are expressed as median and interquartile range. 
P values are calculated versus baseline levels. Grey bars indicate levels measured in a reference population.  
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Data are calculated in the 79 patients who completed the overall follow-up. 
 
FXIIa: activated Factor XII; FXIa: activated Factor XI; C1INH: C1 esterase inhibitor. 
 
Figure 14. Levels of FXIIa-C1INH (A), FXIa-C1INH (B) and Kallikrein-C1INH (C) in patients 
undergoing or not undergoing chemotherapy at 6-month time point.  
 
 
 
 
 
4.6 MV-TF activity: baseline and trend 
Table 19 shows median levels of MV-TF activity in the study population. Particularly, we once again 
detected the highest increase of MV-TF dependent procoagulant activity in pancreatic cancer 
compared to the other cancer subgroups.  
 
Table 19. Baseline MV-TF activity in the study population.  
 Pancreatic cancer Colon cancer 
 
Gastric-
esophageal cancer 
MV-TF activity – pg/mL            0.1 [0.028-0.30] 
(r.v. 0.01-0.06) 
0.072 [0.027-0.18] 0.064 [0.027-0.17] 
Data are expressed as median and range interquartile. 
r.v.: reference values; TF: tissue factor.  
Indicative reference values were calculated in a group of 10 healthy volunteers (half male). 
 
 
The trend of MV-TF activity in the overall population showed a slight increase 7 days post-surgery 
and a progressive decrease during follow-up reaching 6-month time point levels slightly reduced 
compared to baseline. However, differences during the follow-up were not statistically significant 
(Figure 15, panel A). Considering solely the subgroup of pancreatic cancer, patients presented a 
progressive decrease of MV-TF activity over the course of the disease though we did not detect 
any statistically significant differences (Figure 15, panel B).  
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Interestingly enough, levels of MV-TF activity positively correlated with D-dimer (R 0.36 p 0.001) 
(Figure 16). On the contrary, MV-TF activity did not correlate with the contact activation pathway 
(FXIIa-C1INH, FXIa-C1INH and KAL-C1INH) neither in the overall population nor the pancreatic 
cancer subpopulation (data not shown).  
 
Figure 15. Longitudinal trend of MV-TF activity in the overall population (A) and in pancreatic 
cancer (B).   
 
 
 
Data are expressed as median and interquartile range. Grey bars indicate levels measured in a reference 
population.  
P ANOVA for multiple comparisons: 0.04 (A) and 0.036 (B). p values calculated versus baseline levels were 
not statistically significant. 
Data are calculated in the 79 patients who completed the overall follow-up. 
 
 
Figure 16. Correlation between MV-TF activity and D-Dimer. 
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4.7 Baseline levels of microvesicles 
 
4.7.1 Total MVs 
Table 20 shows median levels of total MVs in the study population categorized by cancer type. 
Considering the overall phosphatidylserine-positive events (PS+), we once again showed that 
pancreatic cancer had the highest levels compared with colon and gastric cancers (ANOVA p <0.001) 
(see also Figure 17). Moreover, even considering the subgroups of PS+MVs according to their size 
(big, small and nano), pancreatic cancer showed the highest profile (Table 20 and Figure 17). 
Interestingly enough, the majority of MVs recorded were PS-. However, PS-MVs recorded did not 
differ according to neoplasm type either considering total PS-MVs or PS-MVs subtypes (Figure 17). 
 
Table 20. Baseline levels of total microvesicles (MVs) in the study population.  
 Pancreatic cancer 
 
Colon cancer Gastric-
esophageal cancer 
Total MVs – n/µL 
          PS+                                    55 [29-112] 
          PS-                                 7522 [3196-11594] 
 
24 [13-39] 
7671 [2434-10047] 
 
47 [23-75] 
7607 [1960-10498] 
Total BIG MVs – n/µL 
          PS+                                    83 [32-346] 
          PS-                                 2733 [1734-4157] 
 
38 [20-50] 
1408 [1038-2690] 
 
39 [21-71] 
1395 [1395-871] 
Total SMALL MVs - n/µL 
          PS+                                     92 [43-126] 
          PS-                               10702 [7897-13154] 
 
26 [18-36] 
8747 [7646-10642] 
 
67 [45-93] 
9564 [7893-11602] 
Total NANO MVs - n/µL 
          PS+                                    37 [16-55] 
          PS-                              9520 [7671-10661] 
 
13 [6-21] 
7522 [5539-9405] 
 
35 [18-59] 
9376 [7151-11772] 
Data are expressed as median and range interquartile. 
MVs: microvesicles; PS: phosphatidylserine. 
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Figure 17. Levels of total (PS+ and PS-) microvesicles (MVs). (A and B) total PS+ and total PS-
MVs; (C and D) Total BIG PS+ and total BIG PS- MVs; (E and F) total PS SMALL and total PS- 
SMALL MVs; (G and H) total PS+ NANO and total PS- NANO MVs.  
 
  
 
Data are expressed as median and range interquartile. MVs: microvesicles; PS: phosphatidylserine; Es-Gastric: 
esophageal-gastric.  
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4.7.2 Endothelial MVs 
 
Pancreatic and esophageal-gastric cancer patients also showed the highest number of endothelial-MVs 
(Table 21 and Figure 18). Interestingly, the majority of endothelial events were small.  
 
Table 21. Baseline levels of endothelial microvesicles (MVs) in the study population.  
 Pancreatic 
cancer 
Colon cancer 
 
Gastric-
esophageal cancer 
Endothelial MVs – n/µL             15 [6-36] 7 [4-13] 14 [6-23] 
Endothelial BIG – n/µL              16 [8-85]                 10 [6-17] 11 [6-21] 
Endothelial SMALL - n/µL       25 [10-46] 
                                      
9 [6-17] 24 [15-37] 
Endothelial NANO - n/µL           6 [2-17] 4 [2-6] 8 [5-15] 
Data are expressed as median and range interquartile. 
MVs: microvesicles; PS: phosphatidylserine. 
 
Figure 18. Levels of total endothelial-MVs (panel A) and endothelial-MVs classified by size 
(panel B and C).  
 
Data are expressed as median and interquartile range.  
 
 
4.7.3 Tumour MVs 
 
Table 22 and Figure 19 show levels of tumour MVs measured in the cancer population. Particularly, 
we detected tumour MUC-1+ MVs in pancreatic and gastric cancers and tumour EPCAM+MPVs in 
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colon cancer. Levels of tumour MVs did not vary significantly with the cancer subpopulation. The 
majority of tumour MVs were SMALL.  
 
Table 22. Baseline levels of tumour microvesicles (MVs) in the study population.  
           Pancreatic cancer 
  (MUC-1+)    
Colon cancer 
(EpCAM+) 
Gastric-esophageal 
cancer (MUC-1+) 
Tumour MVs – n/µL                       24 [9-52] 23 [13-42]             19 [9-38] 
Tumour BIG – n/µL                     29 [10-246]                 21 [9-34] 18 [9-27] 
Tumour SMALL - n/µL               40 [28-82] 
                                      
42 [34-85] 47 [34-74] 
Tumour NANO – n/µL                   14 [6-22] 7 [2-13] 10 [5-16] 
Data are expressed as median and range interquartile.  
 
Figure 19. Levels of tumour MVs (panel A) and tumour MVs classified by size (panel B-D).  
 
 
Data are expressed as median and interquartile range.  
 
 
 
4.7.4 Trend of MVs during the follow-up 
 
Figure 20 shows the trend of PS+MVs, endothelial and tumour MVs during the follow-up period in 
the overall cancer population. We observed a slight increase in PS+ and tumour MVs levels 7 days 
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and 1 month after surgery. However, the differences compared to baseline levels were not statistically 
significant. On the contrary, endothelial MVs did not change during the follow-up.  
 
 
Figure 20. Trend of tumour MVs during the follow-up. A) PS+, B) endothelial MVs, C) tumour 
MVs.  
 
 
Data are expressed as median and interquartile range. MVs: microvesicles; PS: phosphatidylserine. 
 
 
 
4.8 MVs correlations with MV-TF activity and coagulation parameters.  
 
In order to evaluate whether circulating MVs carriers a TF-dependent coagulant activity, we 
performed a correlation test between each subtype of MVs considered and MV-TF activity detected. 
Considering the overall cancer population, we showed that MV-TF activity positively correlated with 
big and small endothelial MVs (R 0.319, p 0.038 and R 0.311, p 0.04, respectively), and weakly 
correlated with PS+MVs BIG (R 0.21 p 0.045) (Figure 21, A). When we focused the analysis solely 
on pancreatic cancer (which showed the highest values of MV-TF activity) we observed that (Figure 
21, B): 
- MV-TF activity positively correlated with PS+MVs (R 0.559 p 0.0001), both BIG (R 0.527 p 
0.0001) and SMALL (R 0.556 p 0.007), but not with NANO; 
- MV-TF activity positively correlated with endothelial MVs BIG (R 0.28 p 0.028) and SMALL (R 
0.29 p 0.022); 
- MV-TF activity positively correlated with BIG tumour MVs (R 0.26 p 0.03). 
- MV-TF activity did not correlate neither with NANO MVs nor with PS-MVs.  
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Figure 21. Correlation between circulating MVs and MV-TF activity. A) between MV-TF 
activity and endothelial MV (big and small) and PS+MV BIG in the overall population. B) between 
MV-TF activity and tumour MV, endothelial MVs (big and small) and PS+MVs (big and small) in 
pancreatic cancer. 
 
MPTF: MV-TF activity; EMV: endothelial MVs; MVPSpos: PS+MVs. 
 
 
MPTF: MV-TF activity; Endot: endothelial MVs; MVPSpos: PS+MVs.  
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We also checked for possible correlations between coagulation parameters and MVs. The only 
positive correlation found was between MVs and FVIII levels both at baseline and 7 days post-
surgery. In particular, PS+MV (R 0.36 p 0.002), endothelial MVs (R 0.32 p 0.006) and tumour MVs 
(R 0.28 p 0.015) correlated with FVIII levels (Figure 21, C). Also, MVs levels did not correlate with 
D-dimer and the contact system pathway neither at baseline nor 7 days post-surgery. Finally, we 
observed a positive correlation between all subtypes of MVs and PAI-1 antigen 7 days post-surgery 
(see Figure 21, panel D). Interestingly, the correlation between tumour MVs and PAI-1 antigen was 
highly significant (R 0.44 p <0.0001).   
 
Figure 21. Correlation between circulating MVs with factor VIII and PAI-1 antigen. C) between 
all MVs subtypes and factor VIII levels at baseline; D) between all MVs subtypes and PAI-1 antigen 
7 days after surgery.  
 
Tumour: tumour MVs, PS: PS+MV; EMV: endothelial MVs; F8: factor VIII levels; PAI: PAI-1 antigen.  
 
 
4.9 Circulating MVs as biomarkers for surgical radicality 
 
The second aim of our study was the possible use of MVs as early biomarkers for cancer clinical 
outcomes. Firstly, we evaluated their possible association with surgical radicality. We analysed the 
trend of MV-TF activity and circulating MVs according to surgical radicality and we observed that: 
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- MV-TF activity was significantly higher in patients without surgical radicality at baseline (p 0.005), 
7 months after surgery (0.012) and 1 month after surgery (p 0.029) (Figure 22 panel A-D).  
- circulating MVs (endothelial MVs, PS+MVs and tumour MVs) were significantly higher in patients 
without surgical radicality at baseline, 7 days and 1 month after surgery (Figure 23 panel A-D).  
 
Figure 22. Levels of MV-TF activity in patients with and without surgical radicality.  
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Figure 23. Circulating MVs in patients with and without surgical radicality.  
 
Blue indicates endothelial MVs (EMV), green PS+MVs, and yellow tumour MVs (TUM). P value are 
calculated between patients with and without radicality at the different time points.  
 
Using a Cox proportional Hazard model, we showed that high levels of MV-TF activity, endothelial 
MVs and tumour MVs were associated with a significant risk of incomplete surgical eradication. 
Particularly, MV-TF activity showed a strong association with incomplete surgical radicality (OR 
2.25 [95%CI 1.25-7.0]. The OR was significant even after adjustment for age, Karnofsky 
Performance Status and type of cancer with the presence of esophageal cancer emerging as highly 
predictive of surgical radicality (see Table 23).  
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Table 23. Risk factors for incomplete surgical radicality.  
 β coefficient OR [95%CI] p 
MV TF-activity                                  0.81 2.25 [1.25-7.0]            0.006 
Endothelial MVs                               0.176 1.19 [1.04-1.36]            0.011 
Tumour MVs                                    0.043 1.04 [1.02-1.08]             0.38 
Es-Gastric cancer                              - 3.1 0.45 [0.30-0.72]             0.28 
 
The model was adjusted for age, Karnofsky Performance Status and cancer type (pancreatic, colon and 
esophageal-gastric).  
 
 
 
4.10 Circulating MVs as biomarkers for cancer severity 
 
When cancer patients were considered according to disease severity (localized: stage I-II or advanced: 
stage III-IV), we observed that patients with advanced neoplasm had significantly higher levels of 
MV-TF activity, endothelial MVs and PS+MVs (Figure 24, panel A-C). On the contrary, tumour 
MVs showed a trend towards higher levels in advanced cancer, but the difference was not statistically 
significant. This figure was confirmed also at the 7-day time point when advanced cancer had 
significantly higher levels of MV-TF activity, endothelial MVs and PS+MVs, but not tumour MVs.  
 
Figure 24. Levels of MV-TF activity and MVs in cancer patients with localized or advanced 
disease.  
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Using a Cox proportional Hazard model, we showed that high levels of MV-TF activity and 
endothelial MVs at baseline were associated with a significant risk of advanced neoplasm (see Table 
24).  
 
 
Table 24. Factors associated with advanced cancer.  
 β coefficient OR [95% CI] P 
MV-TF activity                                  0.655 1.87 [1.20-3.8]            0.008 
Endothelial MVs                                0.265 1.30 [1.05-1.6]            0.013 
 
The model was adjusted for age, Karnofsky Performance Status and cancer type (pancreatic, colon and 
esophageal-gastric).  
 
 
 
4.11 Predictors of venous thromboembolism 
 
Overall and as mentioned previously in paragraph 4.2, 15 (16.1%) patients developed VTE over 
follow-up. The median time of the event was 2 months for pancreatic, 3.2 months for colon and 0.5 
month for gastric cancer after the enrollment. A univariate Cox regression analysis was performed in 
order to evaluate coagulation biomarkers potentially predictive of VTE. According to this univariate 
model, variables significantly associated with VTE development were: baseline MV-TF activity, 
baseline FXIa, 7-day endothelial MVs and PS+MVs, baseline fibrinogen and D-dimer. All remaining 
parameters did not show any association with VTE development. After adjustment for possible 
confounders (age, Karnofsky Performance Status, BMI, cancer subtype and severity of disease), the 
variables that still remained significantly associated with VTE occurrence were baseline MV-TF 
activity (HR 2.38 [1.81-4.11]) and baseline FXIa (HR 1.66 [1.02-2.9]) (Table 25 and Figure 26). 
Levels of circulating MVs did not show a significant association with VTE after adjustment for 
confounders.  
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Table 25. Coagulation factors associated with VTE occurrence.  
 Univariate Multivariate 
 β coefficient HR [95%CI] β coefficient HR [95%CI] 
Baseline MV-TF 3.04 20 [5.8-74]   0.867 2.38 [1.81-4.11] 
Baseline FXIa 0.359 1.43 [1.05-2.03] 0.508 1.66 [1.02-2.9] 
7-day endothelial 
MVs 
0.231 1.22 [1.04-2.11] 0.01 1.01 [1.01-10.9] 
7-day PS+MVs 0.183 1.19 [1.06-2.09] 0.075 ns 
Baseline 
fibrinogen 
0.09 1.1 [1.03-1.8] 0.088 ns 
Baseline D-dimer 0.09 1.09 [1.02-1.9] 0.1 ns 
Data were adjusted for age, sex, BMI, Karnofsky Performance Scale, cancer type, surgical radicality and 
severity of disease.  
 
After performing a ROC analysis with MV-TF activity and FXIa levels, we observed that the AUC 
for discriminating between cases (VTE) and non-cases (non-VTE) was highly discriminant for the 
former (AUC 0.9) and a little less discriminant for the latter (AUC 0.71) (figure 25).  
 
Figure 25. ROC curve evaluating VTE diagnostic ability of MV-TF activity and FXIa.  
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The ROC analysis showed that the levels with the highest sensitivity and specificity for VTE were 
0.19 pg/mL (sensitivity 85%, specificity 82%), whereas for FXIa levels of 0.61 nM were associated 
with a sensitivity of 85%, but with lower specificity (70%). A Kaplan-Meier analysis evaluating VTE 
occurrence dividing the cancer population according to MV-TF activity (≥ 0.19 pg/mL) and FXIa (≥ 
0.61 nM) showed a significant risk to develop VTE in patients with levels higher than these calculated 
cut-off (HR 4.7 [95%CI 3.3-12.0]) for MV-TF activity and 3.7 [95%CI 1.29-10.8] for FXIa) (Figure 
26 A and B). HR reported were adjusted for age, sex, BMI, cancer type, severity, and surgical 
radicality.   
 
Figure 26. Kaplan-Meier analysis showing the high risk to develop VTE for patients with high 
levels of MV-TF activity (A) and FXIa (B).  
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5. Discussion 
 
Rationale for the study 
 
It is fully recognized that cancer patients are at significant risk of developing thrombotic events, 
spanning from asymptomatic deep vein thrombosis and catheter-related thrombosis to recurrent deep 
vein thrombosis and massive pulmonary embolism, as well as thrombosis in unusual sites (3, 6). The 
prevention of such complications is of the utmost importance from a clinical standpoint, seeing as 
they play a considerable part in the morbidity and mortality of these patients (79). The main issue is 
that the pathogenesis of the cancer-associated coagulopathy is complex and multifactorial. Even 
without thrombosis, cancer induces different degrees of coagulation activation that can lead to a 
systemic hypercoagulable state owing to a complex interplay among cancer cells, host cells and the 
coagulation system. This interplay involves not only direct activation of coagulation – and ultimately 
thrombin generation – but also the fibrinolytic system, platelets, as well as inflammatory cells and 
their mediators (32, 79, 90). It is also important to remind that several compounding risk factors for 
VTE usually coexist in cancer patients, thus raising the baseline prothrombotic state up to the 
threshold for clinically overt thrombosis. A deep understanding of the mechanisms involved in the 
pathophysiology of hypercoagulability and cancer-associated thrombosis is essential to control the 
“prothrombotic-silent-phase” and properly prevent the event occurrence. Additionally, given the 
multitude of pathways and mediators involved in these pathomechanisms, it is entirely possible that 
each cancer type may be characterized by its own prothrombotic profile depending on site, 
differentiation grade, aggressiveness and host immunological response. The individual characteristics 
of each patient as well as the treatments received over the course of the disease may influence their 
prothrombotic profile. A lot of work has been done so far in an effort to get a better understanding of 
the cancer-induced mechanisms of clotting activation or in the interplay between coagulation and 
inflammation, as well as in the essential role of platelets as cancer mediators in different neoplasms 
(114, 115, 134, 191). Clinically speaking, however, the only current laboratory biomarkers that have 
been shown to have some role in predicting the thrombotic risk of patients are white blood cell and 
platelet counts (33). Several studies have reported that leucocytosis is associated with a greater risk of 
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VTE in cancer patients and leukocytes have also been shown to contribute to VTE in mouse models 
(134). However, leucocytosis was most frequently observed in patients with lung or colorectal 
tumours, while neutrophilia and monocytosis in soft tissue sarcomas (134). Therefore, the clinical 
significance and use of this marker need further clarification. As for platelet count, thrombocytosis 
has often been observed in patients with cancer, especially gastrointestinal, lung, breast, and ovarian 
malignancy. The role of platelets in thrombosis has also been studied in mouse cancer models. Taken 
together, these clinical and basic studies confirm a role for platelets in the pathogenesis of VTE and 
suggest that anti-platelet drugs may be useful in preventing VTE in some cancer patients (68, 70, 134, 
192, 193). Following these observations, the currently available scoring systems use site of cancer, 
leukocyte and platelet counts to identify patients with all types of cancer who are at high risk of VTE 
during chemotherapy (66). However, current scores are heavily weighted on type of cancer, and they 
have been shown to perform poorly in predicting venous thromboembolism in cancer patients (194, 
195). Moreover, leucocytosis and thrombocytosis do not feature in every cancer and sometimes may 
not correlate with leukocytes or platelets activation. Thus, the identification of novel biomarkers 
associated with the grade of hypercoagulability in individual malignancies is required to drive the 
development of cancer-type specific scoring systems with improved predictive value.  
The aim of our study was to assess the trend of several coagulation parameters focusing on patients 
with gastro-intestinal cancer and to determine which parameter may have a role in predicting VTE in 
this subset of malignancy. Particularly, we focused on gastro-intestinal cancer firstly because 
pancreatic and gastric cancers have been shown to be highly associated with VTE complications in 
adult population (incidence rate 14.6 [12.9–16.5] per 100 person-years and 10.8 [9.5–12.3] per 100 
person-years, respectively) (12). As for colon cancer, though associated with an intermediate risk of 
VTE (6.7 [6.3–7.2] x 100 person-years (12)), it is the third most common cancer among men and the 
second among women; the fourth leading cause of cancer-related mortality worldwide; and an 
estimated 5-6% of the Western population will suffer from colon cancer during their lifetime (196). 
Secondly, we decided to homogeneously include only the most common histologic types, such as 
adenocarcinoma and epithelial cancer, excluding histologic types (such as sarcomas, neuroendocrine 
tumours, melanomas, etc) that are less prevalent and can have peculiar clinical behaviours. Regarding 
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the choice of coagulation markers, we focused on coagulation factors associated with both clotting 
activation and acute-phase inflammation, such as factor VIII and fibrinogen. As cancer-induced 
hypercoagulability depends demonstrably on fibrinolytic inhibition, we measured PAI-1 antigen 
levels and D-dimer. Considering the conflicting results yielded by previous studies evaluating the 
impact of factor V Leiden and prothrombin mutation on the risk of thrombosis in cancer, we opted to 
perform the genetic research of the most prevalent hereditary thrombophilia in the present study. 
Additionally, we focused on thromboelastrometric parameters: Rotation ThromboElastoMetry 
analyser (ROTEM®, Tem International, Munich, Germany) is a point-of-care coagulation monitoring 
device which assesses the viscoelastic properties of whole blood in order to study the simultaneous 
and integrated effects of different components (i.e. plasmatic factors, platelets, leukocytes, and red 
blood cells) involved in the dynamic process of clot formation and lysis (184). Thromboelastometry 
has shown tremendous potential in detecting a variety of coagulopathies, including states of hypo- as 
well as hypercoagulability (184). Recent evidence showed that thromboelastometry might be a useful 
tool in the prediction of cancer-associated thrombosis in cholangiocarcinoma (197). In particular, 
inasmuch as the point-of care-nature of the test, it may be a very useful tool in the monitoring of post-
operative cancer-associated hypercoagulability, namely the risk of post-surgical VTE. We also 
focused on the contact activation pathway. Increasing interest in the contact pathway of coagulation in 
the past decade has focused on a possible role in the pathogenesis of thrombosis (198). Moreover, 
preliminary observations have noted the presence of activation of the contact system in 
gastrointestinal, lung, breast and prostate cancers (109, 199). The activation of the contact system in 
cancer might be further enhanced by indwelling ‘foreign’ surfaces (intravenous catheter, port-a-cath), 
and perhaps chemotherapy, concurrent infection and packed red blood cell transfusions as well. 
Finally, we addressed our interest in circulating MVs by measuring either their number in plasma or 
by assessing their antigenic property via flow-cytometry. Given the central role of the TF in the 
cancer-associated hypercoagulability, we further evaluated MV-TF procoagulant activity (96).  
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Primary outcome – fluctuations of coagulation parameters: factors, fibrinolysis and 
thromboelastometry 
 
Our findings showed increased levels of factor VIII at baseline (189% [207-185]) within the subgroup 
of pancreatic cancer, higher than the reference range and compared to other cancer subtypes. On the 
contrary, fibrinogen levels were within the normal range in all cancers considered. As for coagulation 
factors trend, we detected a significant increase both in factor VIII and in fibrinogen 7 days after 
surgery with a slight decrease 1 and 6 months after surgery. Interestingly, levels of factor VIII were 
still higher than baseline 6 months after surgery in the overall cancer population. This result is 
confirmed by evidence in Literature that shows that levels of factor VIII are significantly higher 
among cancer patients. Moreover, in prospective trials, a high factor VIII level is predictive of cancer-
associated thrombosis (200). Factor VIII is an acute-phase protein and it is involved in the interplay 
between coagulation and inflammation. It is important to point out that, besides this increase observed 
in cancer which leads to a chronic persistent low-grade inflammation, interventions like surgery can 
also cause a surge in factor VIII levels that can persist for up to 6 months after the intervention. 
Therefore, strategies to prevent cancer-associated thrombosis may be improved by also considering 
anti-inflammatory agents in high-risk situations; for example, aspirin use was associated with a 
borderline reduction in VTE in patients with ovarian cancer (193). Aspirin may control both 
inflammatory and platelets-mediated hypercoagulability.  
Our findings also showed that pancreatic cancer is associated with higher levels of PAI-1 antigen and 
D-dimer compared to the other subtypes. D-dimer markedly increased soon after surgery, but then 
rapidly decreased 1 month after. PAI-1 levels did not change much after surgery and during the 
follow-up. There are few studies evaluating the fibrinolytic system in cancer associated-thrombosis. A 
study conducted on patients with pancreatic cancer suggested that elevated levels of PAI-1 antigen 
and activity may predispose patients to VTE (201). Another study found higher levels of PAI-1 in 
glioma patients compared with healthy controls (202). Oncogene activation, and perhaps hypoxia, 
have been shown to inhibit fibrinolysis by up-regulating PAI-1 in cancer (203). Moreover, as 
previously mentioned, PAI-1 mRNA was  detected  in  endothelial  cells  originating from  the 
tumours in patients with colorectal cancer, thus directly bestowing cancer cells with the capability to 
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inhibit fibrinolysis (113). According to our results, surgery did not appear to worsen this 
hypofibrinolytic tendency of cancer, being the traumatic activation of coagulation and fibrinolysis the 
most important pathway involved (as evidenced by the marked increase of D-dimer soon after 
surgery). Interestingly, administration of the anti-VEGF drug bevacizumab increased thrombosis in 
two mouse models. Bevacizumab increased PAI-1 expression in tumours and in plasma leading to 
enhanced thrombosis that was reduced by a PAI-1 inhibitor (134).  
A few words regarding our findings on thromboelastometry in cancer. Baseline ROTEM® parameters 
were within the normal range. Baseline FIBTEM MCF (the strength of the coagulum – a functional 
test for fibrinogen) was higher in pancreatic cancer compared to the other subtypes. Moreover, after 
surgery there was a prompt increase in the MCF in the three tests considered (INTEM-EXTEM and 
FIBTEM). These findings mirror the post-surgical phase of coagulation activation. In a recent study 
involving 27 patients with cholangiocarcinoma, MCF showed a non-significant trend of increased 
levels in the 6 patients who developed post-operative VTE (197). We can speculate that the 
ROTEM® parameter MCF may be a useful tool to monitor global coagulation changes after surgery, 
in order to potentially early detect those cases with particularly high post-surgical acute 
hypercoagulability that may benefit from “potentiated” thromboprophylaxis or thromboprophylaxis 
combined with compounds targeting different pathways.  
 
Primary outcome – fluctuations of coagulation parameters: contact system activation 
 
Interestingly enough, by measuring plasma complexes between contact system factors and their main 
inhibitor, we uncovered increased baseline levels compared to levels measured in a reference healthy 
population. Pancreatic and gastric cancers showed the highest activation. This means that the intrinsic 
pathway is also part of the coagulation activation in cancer. More interestingly, surgery did not seem 
to affect contact system, in fact complexes levels did not change 7 days after surgery. On the contrary, 
FXIIa-C1INH and FXIa-C1INH complexes slightly increased 1 month and 6 months after surgery. In 
particular, patients receiving chemotherapy at the 6-month time point showed significantly higher 
levels of FXIIa-C1INH and kallikrein-C1INH complexes compared to patients without chemotherapy. 
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This result is of great interest, because it highlights the possible role of chemotherapy in worsening 
cancer prothrombotic profile by enhancing the intrinsic pathway. Given also that most patients 
undergoing chemotherapy have external devices, like central vein catheters or port-a-cath, the 
presence of these surfaces may also potentiate this contact system activation ultimately leading to the 
thrombotic event. Thrombotic events in cases like this may stem from increased thrombin-generation 
driven by the intrinsic pathway rather than by the TF pathway. Our findings confirm the results of a 
past study presented in 1990 (199). Contact system activation was evaluated in 69 patients with 
gastrointestinal cancer (12 with gastric, 15 with pancreatic and 42 with colon cancer), and in 118 
healthy controls. The authors found reduced levels of factor XII, pre-kallikrein and high molecular 
weight kininogen in cancer compared with controls, whereas C1INH antigen and activity were 
significantly increased in cancer compared with controls. The reduced levels of non-activated factors 
and the increased levels of the inhibitor were interpreted as an indication of recent activation of the 
contact system. Furthermore, patients with metastatic cancer showed a contact system “more 
activated” than non-metastatic cancer patients. It is important to note that although several 
observations have documented the activation of the contact system in different cancers, the underlying 
mechanism(s) remain(s) elusive. Recently, Nickel et al. (109) demonstrated that prostate cancer cells 
secrete exosomes (prostasomes) that induce lethal pulmonary embolism in mice and can trigger 
thrombin generation in vitro in a dose-dependent manner. The addition of a recombinant FXIIa 
inhibitor significantly reduced peak and total thrombin generated by prostasomes; the combined 
application of FXIIa and TF inhibitors completely stunted thrombin generation. Thus, both the 
intrinsic and extrinsic pathways seemed to contribute to thrombosis in this model. Moreover, 
polyphosphate P (PolyP) was found on the surface of prostasomes. Treatment of prostasomes with 
specific inhibitors of PolyP or with PolyP degrading enzymes abrogated prostasome-induced FXIIa 
generation in vitro and protected mice from prostasome-induced lethal pulmonary embolism. In 
aggregate, these findings showed a role for the prostasome – FXII axis mediated by PolyP in the 
increased procoagulant activity observed in prostate cancer. The confirmation of these findings may 
open up a new clinical scenario where compounds targeting contact system activation may be used to 
prevent thrombosis when the intrinsic pathway is more involved, for example - according to our 
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results - during chemotherapy or catheter-related thrombosis. It is a well-established fact that genetic 
or pharmacologic inhibition of FXIIa is protective against thrombosis in mouse models of arterial and 
venous thrombosis without any associated haemorrhagic diathesis (204). Several classes of contact 
system inhibitors are under development as thrombo-protective and/or anti-inflammatory agents 
(205).  
 
Primary outcome – fluctuations of coagulation parameters: MV-TF activity 
 
As far as MV-TF activity is concerned, the highest levels were detected in pancreatic cancer. 
Globally, we saw a slight increase 7 days after surgery and a progressive decrease over follow-up 
with the 6-month time point levels slightly reduced compared to baseline. Moreover, MV-TF activity 
significantly correlated with D-Dimer. Several studies have examined the relationship between TF-
MVs and VTE in patients with pancreatic, brain, colorectal, or lung cancer. TF-MVs were detected in 
all these neoplasms but patients with pancreatic cancer showed the highest levels of MV-TF activity 
(170). One possible explanation for these findings is that the endocrine function of the pancreas 
provides an easy route for transporting TF-MVs from the tumour into the bloodstream (134). We 
confirmed the presence of MV-TF activity in pancreatic cancer and observed that while levels of MP-
TF activity did not appear to be affected by surgery or chemotherapy, it was a marker related of the 
“tumour activity” itself. Indeed, it slowly decreased during the follow-up period with some patients 
going into remission, but most importantly, it was significantly associated with surgical radicality and 
tumour severity. We found that MV-TF activity was already significantly higher at baseline in 
patients without surgical radicality, 7 months after surgery up to 1 month after surgery. Moreover, at 
baseline patients with advanced neoplasm had significantly higher levels of MV-TF activity. One 
important observation is that, in a multivariate model, baseline levels of MV-TF activity were 
independent predictors of incomplete surgical removal (with a risk of 2.25 [1.25-7.0]), as they were 
also significantly associated with cancer severity (baseline high MV-TF activity was associated with 
1.87 risk to have advanced cancer). The results were confirmed after adjustment for cancer type.  
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Primary outcome – fluctuations of coagulation parameters: circulating MVs 
 
When focusing on circulating MVs, we observed that pancreatic cancer had higher levels of total 
MVs (i.e. PS+MVs), higher endothelial MVs and tumour MVs (detected by MUC-1 antigen). 
Interestingly, with the new-generation flow-cytometer, we are now able to differentiate MVs 
according to their size. Old flow-cytometric assays were not sensitive enough to detect all sizes of 
MVs, given that many of these fall below the detection threshold. In particular, small and nano-MVs 
were missed. We observed that the majority of detected MVs were small (diameter 0.2-0.4 µm). 
Moreover, we confirmed that PS-MVs are the majority and thus PS is not the perfect marker to detect 
total number of MVs. However, PS-MVs did not show a specific pattern according to the cancer 
population and did not correlate with MV-TF activity. It is widely accepted that MVs expose 
phosphatidylserine which in turn binds annexin V. A number of recent reports have questioned the 
use of annexin V for MV detection, stating that a subpopulation of MVs do not demonstrate 
detectable levels of annexin V binding (206). There may be a number of explanations for failure to 
detect MVs annexin V binding, including inadequate experimental conditions to allow maximal 
annexin V binding (calcium concentration) or the presence of inhibitors to annexin V binding. 
Alternatively, decreased or absent annexin V binding may simply result from insufficient PS exposure 
on the membrane surface to allow detectable annexin V, thereby representing true annexin V negative 
MVs. Finally, it is possible that these events may not represent MVs at all, but instead platelet-derived 
exosomes (resulting from platelet activation), small platelets or the remnants of activated platelets, 
possessing scattering properties of similar magnitude to MVs. It is worth mentioning that Connor et 
al. (206) showed that in unstimulated platelet-poor plasma, 80% of platelet-derived MVs failed to 
bind annexin V and the variation of the assay constituents (buffer, calcium and annexin V 
concentration) did not increase annexin V binding. However, after in vitro platelets stimulation, the 
percentage of total events that bound annexin V was dependent upon the type of agonist used. 
Moreover, the expression of platelet activation markers CD62P and CD63 was significantly decreased 
in annexin V-MVs, compared to annexin V+MVs, suggesting that the latter are associated with a 
greater degree of platelet activation. Therefore, Annexin+ events seem to reflect the subgroup of MVs 
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released after cell activation, the most useful from a clinical point of view. Indeed, we showed that 
only PS+MVs positively correlated with MV-TF activity, confirming that PS+MVs, and not PS-
negative, confer the procoagulant activity. Connor et al. (206) also found that the majority of 
procoagulant activity was associated with the annexin V binding subpopulation using a phospholipid-
dependent clotting time. We added the fact that our functional test measured the procoagulant activity 
due to TF, and we were able to confirm that PS+MVs had procoagulant potential also by expressing 
TF. Interestingly, MV-TF activity correlated with big and small MVs, and not with the NANO ones. 
Finally, the procoagulant activity also correlated with endothelial MVs and BIG tumour MVs, 
confirming the expression of TF in these subgroups of MVs. A number of investigators have since 
considered alternatives to annexin V as a marker of PS exposure (lactadherin, diannexin). 
Nonetheless, annexin V binding remains the most frequently-used marker for MV detection at the 
moment.  
As for the trend of MVs, PS+MVs and tumour MVs showed an increased trend after surgery up to 6 
months of follow-up, but we did not detect any significant differences compared to baseline levels. 
Similarly to MVs-TF activity, it seems that the presence of MVs in plasma is related to the presence 
of tumour itself, rather than to other events (e.g. chemotherapy, surgery). Endothelial MVs, as well as 
MV-TF activity, showed a positive association with surgical radicality and tumour severity. We 
detected an adjusted significant (albeit low) risk of 1.19 [1.04-1.36] to have incomplete cancer 
resection and of 1.30 [1.05-1.6] to have advanced cancer disease according to baseline levels of 
endothelial MVs.  
In summary, MV-TF activity, presumably conveyed by endothelial MVs, proved to be an early 
biomarker of cancer aggressiveness and surgical radicality. MVs levels in cancer patients with 
incomplete surgical resection remained higher than in patients with complete resection up to 1 month 
after surgery. Finally, it is worth mentioning that all MVs subtypes were shown to correlate with 
factor VIII activity, both at baseline and 7 days after surgery. This observation confirmed the role of 
MVs as, not only procoagulant carriers, but also common mediators between coagulation and 
inflammation. As we mentioned in the introduction, endothelial MVs have a role in promoting platelet 
aggregation by bearing von Willebrand factor, this property may be mediated by factor VIII (145). 
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Although a few reports observed a possible activation of the intrinsic pathway mediated by MVs (109, 
136), we found that MVs did not correlate with contact activation complexes. Therefore, MVs do not 
appear to act as an intrinsic pathway activator in gastro-intestinal cancer.  
A brief comment regarding the correlation we found between all subtypes of MVs and PAI-1 antigen 
7 days after surgery. This observation confirms the possible role of MVs as regulator of the 
fibrinolytic system. It is plausible that in a situation characterized by enhanced fibrinolytic activity 
(e.g. post-operative period), MVs may act as fibrinolytic brake (expressing PAI antigen) in order to 
avoid hyperfibrinolysis (126, 143).  
 
Secondary outcomes – association between coagulation parameters and clinical outcomes 
The second aim of our study was to evaluate the possibility to detect a coagulation biomarker able to 
early predict which patient will suffer thrombotic complications. We found that baseline MV-TF 
activity and baseline FXIa were independently associated with VTE occurrence. Levels of MV-TF 
activity ≥0.19 pg/mL conveyed a 2.38 [1.81-4.11] HR for VTE. Furthermore, baseline levels of FXIa 
>0.61 nM conveyed a 1.66 [1.02-2.9] HR to develop VTE over a median follow-up period of 6 
months after diagnosis. This predictive model was adjusted for age, sex, BMI, cancer type, severity, 
and surgical radicality. Importantly, in the univariate model we singularly included all coagulative 
parameters individually, as well as the presence of hereditary thrombophilia. Only MV-TF activity, 
FXIa, fibrinogen, D-dimer, as well as 7-days PS+MVs and 7-days endothelial MVs showed an 
association with VTE occurrence. After adjustment for confounding factors, only MV-TF activity and 
FXIa were still significant.  
 
Main findings 
In the current scenario where many studies have been conducted or are in progress with the main 
purpose of identifying the perfect biomarker or the most accurate predictive model for cancer-
associated thrombosis, the importance of our results lies in the confirmation of MV-TF activity – a 
functional test to detect plasma procoagulant activity associated with TF-bearing MVs – as an 
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independent predictive biomarker of cancer aggressiveness and VTE occurrence, not only in 
pancreatic but also in colon, stomach and esophagus cancer. Additionally, our findings highlight the 
importance of the intrinsic pathway in the pathophysiology of cancer-associated thrombosis. The 
mechanisms of FXI activation requires further elucidation; there is the possibility of direct activation 
of FXIa by cancer (or cancer-released mediators), or FXI activation could be the result of the 
enhanced thrombin generation via the TF pathway. More studies are required to understand the 
contribution of all possible candidates to FXI activation. As TF is upregulated in cancer, it seems 
reasonable to hypothesize that concomitant activation of both the intrinsic and extrinsic pathways may 
act synergistically to produce a highly prothrombotic state in cancer. It is tempting to speculate that 
while TF is the primary initiator, contact system activation may contribute to the amplification of 
thrombin generation in cancer-associated thrombosis. Further studies are required in order to better 
understand FXI activation in various cancer types, stages and phases of the disease.  
 
Limitations 
Our study does have a few limitations. Firstly, the sample size is too small to adequately design a 
predictive model for cancer-associated thrombosis. Nevertheless, we collected a very homogenous 
population that was followed very tightly from a clinical and laboratory point of view. In particular, 
pre-analytic conditions for sample collection and processing were precisely observed (149, 162). 
Secondly, flow-cytometry analysis and contact system measurement are not standardized methods at 
the moment. For the implementation of the former, we strictly followed the current recommendations 
from the International Society of Thrombosis and Haemostasis for flow-cytometry setting and MVs 
analysis (163). For the latter, home-made ELISAs were performed following the best method 
described in Literature at the moment (185-187). Thirdly, we did not evaluate the presence of platelet 
or leukocyte-derived MVs, well-known mediators of cancer-associated hypercoagulability. The 
measurement of these MVs subtypes would certainly add information regarding MVs TF-mediated 
hypercoagulability.  
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Conclusions 
In conclusion, we showed that hypercoagulability in gastro-intestinal cancer is mainly mediated by 
high levels of factor VIII, increased levels of complexes derived from the activation of the contact 
system, high MV-TF activity and increased levels of PS+MVs, endothelial and tumour MVs. These 
prothrombotic factors remained altered up to 6 months after surgical resection of the neoplasm even 
in patients with surgical radicality, indicating that cancer-associated hypercoagulability persists for 
months after tumour removal. Increased MV-TF activity and endothelial MVs are independent 
predictors of advanced disease and incomplete surgical resection. Finally, increased baseline levels of 
MV-TF activity and FXIa were independent predictors of VTE occurrence over the 6 months 
following cancer diagnosis.  
Future research should focus on the standardization of methods to measure MVs and contact system 
activation in plasma. Studies with wider populations are then needed to confirm the predictive role of 
these biomarkers in a wide range of neoplasms. Once the pathways involved are clarified, therapeutic 
options targeting these pathways could be tested and finally tailored to each specific cancer case. 
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